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1. INTRODUCTION 
1.1 Definitions 
1.1.1 COPD 
Chronic obstructive pulmonary disease is defined by the American Thoracic 
Society (ATS) and the European Respiratory Society as “a preventable and treatable 
disease state characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory 
response of the lungs to noxious particles or gases, primarily caused by cigarette 
smoking. Although COPD affects the lungs, it also produces significant systemic 
consequences“ (Siafakas, 2006). According to the Global Initiative for Chronic 
Obstructive Lung Disease, COPD is “a preventable and treatable disease with some 
significant extra-pulmonary effects that may contribute to the severity in individual 
patients. Its pulmonary component is characterized by airflow limitation that is not 
fully reversible. The airflow limitation is usually progressive and associated with an 
abnormal inflammatory response of the lung to noxious particles or gases (Celli et al., 
2004). 
This chronic innate and adaptive inflammatory response results in a tissue 
remodeling process that affects both the large and small airways and may produce 
lesions similar to four different pathologic conditions: chronic bronchitis (central 
airways) (Di Stefano et al., 1996; Kemeny et al., 1999; Mullen et al., 1985; 
O’Shaughnessy et al., 1997; Reid, 1960; Saetta et al., 1993; Saetta et al., 1994; 
Saetta et al., 1997), small airways disease (Hogg et al., 1994; Hogg et al., 2004; 
Wright et al., 1984), emphysema (parenchyma)  (Leopold and Gough, 1957; McLean, 
1957a; McLean, 1957b; McLean, 1958; Retamales et al., 2001) and pulmonary 
hypertension (Elwing and Panos, 2008; Peinado et al., 2008; Weitzenblum and 
Chaouat, 2005; Wright et al., 2005). The phenotype of the disease in patients is 
dependent on the combination of the presence of these conditions and their severity 
and prominence. The main etiologic factor of COPD in the developed world is 
cigarette smoking while other factors like environmental or professional exposure to 
particles and gases, air pollution, biomass smoke, asthma and airway 
hyperresponsiveness are also important.  The classification of COPD into four stages 
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according to the airflow limitation (in subjects with an FEV1/FVC < 0.70 measured 
with post-bronchodilator lung function) is:  
• Stage 1 (mild, FEV1 ≥ 80% predicted) 
• Stage 2 (moderate, 50% < FEV1 < 80% predicted)  
• Stage 3 (severe, 30 < FEV1 < 50% predicted)  
• Stage 4 (very severe, FEV1 < 30% predicted) 
 
as adopted by the GOLD and the ATS/ERS guidelines (Celli et al., 2004). 
1.1.2 Chronic bronchitis 
Chronic bronchitis was defined at the CIBA Guest Symposium in 1959 as the 
presence of a productive cough for more than 3 months in two successive years in 
subjects after the exclusion of other causes of chronic cough, (e.g. tuberculosis, lung 
cancer, heart failure). Chronic bronchitis is seen in 14-74% of patients with COPD  
(Agusti et al., 2010; Burgel et al., 2009; de Oca et al., 2012; Kim et al., 2011b). The 
chronic cough is dose-related to cigarette smoking (Janson et al., 2001). Cigarette 
smoke is the stimulus (Fischer and Voynow, 2002; Gensch et al., 2004; Shao et al., 
2004; Verra et al., 1995) that produces an inflammatory response in the epithelium of 
the central (cartilaginous) airways and the mucus producing glands located there 
(Hogg, 2004). This leads to goblet cell metaplasia and an increase of goblet cell 
numbers (Jeffery, 2000) which in turn results in an excessive production and 
secretion of mucus combined with a decreased elimination caused by impaired 
mucociliary action, occlusion of the distal airways and reduced peak expiratory flow 
(Danahay and Jackson, 2005; Vestbo, 2002). Chronic bronchitis further worsens the 
decline in quality of life (Kim et al., 2011a; Kim et al., 2011b), lung function (Vestbo et 
al., 1996), increases exacerbations (Burgel et al., 2009; Kim et al., 2010; Seemungal 
et al., 2009) and mortality (Guerra et al., 2009).  
1.1.3 Small airways disease 
The small airways of the lungs (less than 2 mm in diameter) are considered to 
be the site where obstruction occurs and where increased resistance of the lungs is 
present (Hogg et al., 1968; Yanai et al., 1992).  The pathological lesions of small 
airways disease (chronic bronchiolitis, respiratory bronchiolitis) are similar to those of 
chronic bronchitis (thickening of the airway walls, increased number of goblet cells, 
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goblet cell metaplasia, smooth muscle hypertrophy) (Cosio et al., 1978; Saetta et al., 
2000).  Combined with airway wall inflammation, that could lead to the destruction of 
the alveolar walls directly attached to the outer surface of small airway walls (Saetta 
et al., 1985), this results in the deformation of the airway walls and the decrease of 
their lumen’s diameter.  In addition, the hyperproduction of mucus, also facilitated by 
the secretion of neutrophil elastase (by the increased number of neutrophils in the 
site), a known secretagogue  (Nadel, 1991), contributes to the obstruction.   
1.1.4 Emphysema 
Emphysema is the abnormal, permanent enlargement of the airways distal to 
the terminal bronchiole, accompanied by destruction of their walls, without any 
obvious fibrosis (Snider et al., 1985). The emphysematous lesions were first 
described by J. Laennec, the inventor of the stethoscope, in his book De 
l'Auscultation Médiate (1819). The elastic recoil of the emphysematous lungs is 
decreased and this leads to a decreased expiratory flow.  Lesions can also be found 
in subjects with normal lung function.  The form of emphysema usually associated 
with cigarette smoking is the centriacinar type in which the destruction is localized in 
the central part of the acinus and confined to the respiratory bronchioles while the 
surrounding areas appear normal.  Centriacinar emphysema is more severe in the 
upper lung lobes (Mahadeva and Shapiro, 2005). 
1.1.5 Pulmonary hypertension. 
Pulmonary hypertension (PH) can be associated with COPD. Recent studies 
have shown that the pathophysiology of pulmonary hypertension in COPD is more 
complex than permanent medial hypertrophy of pulmonary vessels (Barbera et al., 
2003; Naeije, 2005; Peinado et al., 2008; Shujaat et al., 2007; Wright et al., 2005). It 
is now suggested that there is extensive vascular remodeling that leads to more 
severe PH than previously accepted. The increase in mean pulmonary artery 
pressure (mPAP) is 25 to 35 mmHg with a normal cardiac output, even though 
pressures higher than 40 mmHg may also be observed. The severe PH in COPD can 
eventually lead to right sided heart failure by increasing the right ventricular afterload 
(Naeije, 2005). 
1.1.6 Epidemiology – Prevalence – Incidence 
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COPD is one of the major causes of mortality and morbidity worldwide and is 
prevalent in developed as well as in developing countries. It was the sixth leading 
cause of death in 1990, became fourth since 2000 and is predicted to be third by 
2030 (Molina París, 2013). COPD accounts for 2.9 million deaths per year, slightly 
under HIV/AIDS, and for ≈ 2% of disability caused by disease. Studies have reported 
a prevalence of COPD that ranges from 0.2% in Japan  (Tatsumi, 2001) to 37% in 
the USA  (Ohar et al., 2010). Reported prevalence varies according to the method 
used to diagnose and classify COPD and when spirometry is used with combination 
of the GOLD criteria the estimates are greater (Hnizdo et al., 2006; Lindberg et al., 
2005a; Lindberg et al., 2006). 
While the concept of an existence of a susceptible group of smokers is 
popular, the notion that only 15% of smokers develop COPD (Fletcher Charles, Peto 
Richard, Tinker Cecily, 1978) might be misleading (Rennard and Vestbo, 2006). Most 
probably, with enough smoking, 50% of all smokers could develop COPD even if not 
presenting disabling respiratory problems but still fulfilling the diagnostic criteria 
(Rennard and Vestbo, 2006). The incidence of COPD was greater in men and in 
ages over 75 years, but it has started to increase in women and adolescents, most 
probably due to a change of cultural standards and smoking habits. 
1.2 COPD clinical manifestations 
1.2.1 Cough and sputum 
The main characteristic symptoms of COPD are dyspnea, chronic cough, and 
sputum production although the last two do not necessarily mean that the disease is 
already established, as they can precede it for many years without a decrease in lung 
function.  Chronic cough or sputum are present in 15-44% in men and 6-17% in 
women and increase with age (Berkhof et al., 2012).  Changes in these symptoms 
are closely related to smoking status (Viegi et al., 2007). 
1.2.2 Dyspnea 
Dyspnoea is the unpleasant sense of breathlessness and the major symptom 
of COPD while at the same time the main reason for which subjects seek medical 
consultation. Dyspnea is a symptom of cardiovascular and respiratory pathological 
conditions that is usually described by patients as short breath, air hunger, difficult 
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breathing. Dyspnea suggests an imbalance between the demand on one side and 
the ability on the other for ventilation. It is therefore present when the need for 
alveolar ventilation is increased (e.g. increase of metabolic rate) or when the 
ventilation ability and gas exchange is compromised (e.g. cardiovascular and 
respiratory disease). As lung volume increases greater breathing effort is required to 
maintain a constant respiratory volume. In the late onset of the disease this may be 
absent or related to exercise, but in advanced stages it can also be observed at rest 
(Antoniu, 2010). 
1.2.3 Systemic manifestations 
Although COPD is considered primarily a lung disease, studies have shown 
that it also presents extra-pulmonary manifestations. One of the common complaints 
of patients is exercise limitation that could be attributed to the airflow limitation and 
the subsequent increased breathing effort and dynamic hyperinflation (Celli et al., 
2004; Pauwels et al., 2001; Siafakas et al., 1995). However, studies have also 
attributed it to skeletal muscle dysfunction (Donaldson et al., 2012; Furness et al., 
2012; Hussain and Sandri, 2013; MacNee, 2013; Roca and Mihăescu, 2012; 
Seymour et al., 2012; van den Borst et al., 2013). Patients with severe emphysema 
have either a great weight loss or changes in body mass index which is also an 
important predictor of increased mortality, independent of poor lung function. This 
weight loss is associated with increased TNF-α levels (circulating, soluble receptors, 
released from circulating cells) (Agustí et al., 2003; Di Francia et al., 1994).The 
weight loss is also attributed to increased metabolism and skeletal muscle loss, 
particularly lower limb muscles. The muscle weakness results from chronic hypoxia, 
immobility and increased metabolic rate. Due to the breathlessness and the fatigue, 
patients often remain inactive by choice or adopt a sedentary way of life. 
In addition to the lung inflammation, a similar inflammatory response is 
observed on a systemic level. This response involves a systemic oxidative stress, 
inflammatory cells and cytokines in the systemic circulation (neutrophils, 
lymphocytes, TNF-α and its receptors, IL-6, IL-1β, GM-CSF). Finally, other extra-
pulmonary effects are cardiovascular, nervous system and osteoskeletal. 
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1.3 Risk factors 
The risk factors for COPD can be attributed either to the patient (host related) 
or to the environment (exposures) and the combination of both leads to the 
development of the disease. 
1.3.1 Host factors 
1.3.1.1 Genetic factors 
The best documented hereditary deficiency that increases the risk of 
developing COPD is that of α1-antitrypsin responsible for the disease in 1-3% of 
patients (Stoller and Aboussouan, 2005). A1-antitrypsin (α1-AT), encoded by the 
gene SERPINA1, first described in 1963 by Laurell and Eriksson, is a serine protease 
inhibitor that inhibits neutrophil elastase, proteinase 3, and cathepsin G and is part of 
the protection of the lung against elastolytic damage. Furthermore, it blocks the pro-
inflammatory effects of human neutrophil peptide and regulates expression of TNF-α, 
interleukin-6, interleukin-8, interleukin-1β and monocytes chemoattractant protein 1 
(MCP-1). The allele associated with the most severe form of disease is Z (population 
frequency 1%) although not all PI Z smokers have been seen to develop COPD 
(Silverman, 2002). In the most severe form of α1-AT deficiency (piZZ) the Z α1-AT 
also polymerizes and acts as a chemoattractant for neutrophils (Mulgrew et al., 2004; 
Parmar et al., 2002) leading to a further amplification of inflammation. In patients 
suffering from this form there is an increase of neutrophil numbers and a decrease in 
anti-elastase concentration which nevertheless remains active. Other genes that 
have been studied in this context are genes encoding matrix metalloproteinases and 
in particular, MMP 9 and MMP 12, TGF-β1 (Celedón et al., 2004), TNF-α etc. 
1.3.1.2 Airway hyperresponsiveness 
Airway hyperresponsiveness and childhood asthma have been characterized 
as markers of susceptibility to lung function decline.  In a lot of cases, COPD in adult 
smokers has been traced back to episodes having occurred in childhood (Gold et al., 
1989; O’Connor et al., 1995).  Airway hyperresponsiveness accelerates the decline in 
FEV1 (Rijcken et al., 1995). The degree of its severity correlate with an increased 
decline  (Tashkin et al., 1996; Tracey et al., 1995).  
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1.3.1.3 Gender 
Historically, men have been considered to be more susceptible to the 
development of COPD. But it has been demonstrated that during the past decades, 
while death rates in males have been stabilizing, they have been increasing in 
women (Mannino et al., 1997).  Data suggests that women are more susceptible to 
COPD (greater susceptibility to the effects of cigarette smoke, more likely to produce 
antibodies, more severe small airway disease, greater airway hyperresponsiveness, 
larger airways) (Chen et al., 1991; Leynaert et al., 1997; Lombardi et al., 2011; 
Prescott et al., 1997; Ucińska et al., 2012). 
 
1.3.2 Environmental Factors 
1.3.2.1 Cigarette smoke 
Cigarette smoke is the most important risk factor for the development of COPD. 
Active smoking accounts for most cases of COPD in developed industrialized 
countries, but passive smoking is also a risk factor. There is a causal relationship 
between active smoking and COPD morbidity and mortality. An increase in the 
number of cigarettes smoked increases the respiratory symptoms and lung function 
decline and smoking cessation decreases the severity of the symptoms ((US) and 
Surgeon General, 2004; Doll et al., 2004; Eagan et al., 2004) and returns the rate of 
decline to that of never-smokers. 
Cigarette smoke is a complex mixture of >5000 chemicals (Talhout et al., 
2011). It is constituted by a particulate phase (either solid or liquid droplets, more 
stable, >1017 free radicals/gram) in a gaseous phase (less stable, >1015 free 
radicals/puff). More than 200 of these chemical substances have been characterized 
as toxic to humans and animals (DeMarini, 2004; Husgafvel-Pursiainen, 2004). 
Cigarette smoke can be distinguished in three types: mainstream smoke (smoke that 
comes from the mouth end of the cigarette and inhaled by the smoker), side-stream 
smoke (smoke that comes off the burning end of the cigarette when the smoker 
puffs) and environmental smoke (the mixture of the two previous ones when the 
smoker exhales, diluted in the surrounding air). There are significant differences 
between the three. Side-stream smoke contains higher levels of many hazardous 
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chemicals than mainstream smoke (Brunnemann et al., 1990; Evans and Sefton, 
1992; Grimmer et al., 1987; Pakhale and Maru, 1998; Rodgman et al., 2000).  
Furthermore, other factors affecting the smoke composition is the smoking 
pattern, the type of wrapping material (paper or not, type of paper), the additives, the 
type of tobacco ((US) and Surgeon General, 2004). There are numerous chemical 
compounds in cigarette smoke like semiquinones, hydroquinones and metals that 
increase the oxidative burden, counteract the antioxidant firewall and lead to the 
formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
The tar phase of smoke contains transition metals like iron that can promote the 
formation of hydroxyl radicals via Fenton/Haber-Weiss reactions in the lung epithelial 
lining fluid or form complexes with organic molecules that undergo redox cycling  
(Kirkham and Rahman, 2006; Li et al., 2008). The most important effects of smoke 
will be discussed in the oxidative stress section of this introduction. Cigarette smoke 
also leads to the release of numerous inflammatory mediators. The participation of 
smoke in the pathogenesis of COPD involves: 
 
I. Damage to nucleic acids, proteins and lipids (Birben et al., 2012; Bowler et al., 
2004). 
II. Pro-inflammatory activity (Witherden et al., 2004) 
III. Inactivation of protease inhibition (Janoff and Carp, 1977) 
IV. Depletion of antioxidants (Rahman, 2005) 
V. Participation in carcinogenesis (Massion and Carbone, 2003; Witschi et al., 
1997) 
VI. Decreased binding of steroid receptors (Barnes, 2010) 
1.3.2.2 Air pollution 
Outdoor and indoor pollution has a clear association with COPD (Bernstein et 
al., 2004; Bernstein et al., 2008). Outdoor pollution is furthermore one of the 
exposures present throughout a person’s life span. Gaseous or particulate pollutants 
either emitted directly into the atmosphere (SO2, NOx species, CO particulate matter) 
or formed as secondary products of chemical reactions (ozone, particulates, etc.) 
deriving from a variety of sources (indoor and outdoor) can cause adverse health 
effects. A correlation between pollutant levels and lung function decline has been 
reported by a number of studies (Hogervorst et al., 2006; Holguin et al., 2007). A 
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major source of indoor pollution is the use of biomass fuel as domestic energy source 
and cooking which accounts for 50% of deaths from COPD affecting mostly women 
(75%) (Peña et al., 2000). According to the World Health Organization (WHO), about 
50% of households and 90% of rural households worldwide use biomass fuel or coal. 
1.3.2.3 Occupational exposures 
About 15% of COPD cases can be attributed to occupational exposure 
(Balmes et al., 2003; Blanc and Torén, 2007).  People being exposed to toxic gases 
in the working environment, farmers exposed to grain dust and factory workers 
exposed to fumes and dust have a greater risk of developing COPD (Becklake, 1989; 
Bergdahl et al., 2004; Degano et al., 2012; Diaz-Guzman et al., 2012; Jaén et al., 
2006; Lindberg et al., 2005b; Montnémery et al., 2001; Schachter et al., 2009; Shaikh 
et al., 2012; Sunyer et al., 2005; Voisin and Wallaert, 1992; Zock et al., 2001). It has 
also been reported that in diagnosed patients past occupational exposures increase 
the likelihood of developing COPD (Trupin et al., 2003). 
1.3.2.4 Other factors 
While a decrease in lung function is unavoidable with age, COPD prevalence, 
morbidity and mortality all increase also in elderly individuals. Studies since the early 
1970s have shown a correlation between lung function impairment and 
socioeconomic status (Bakke et al., 1995; Cohen et al., 1977; Hole et al., 1996; 
Marmot et al., 1984).  Poor socioeconomic status is correlated with other factors that 
can increase the risk for COPD like intrauterine growth retardation, childhood lung 
infections, poor nutrition (lower antioxidant intake), increased use of biomass fuel, 
high work exposures and increased smoking rates, poor access to medical care and, 
poor housing conditions. 
1.4 Pathophysiology of COPD 
The three main mechanisms that contribute to the pathogenesis of COPD are 
inflammation (lung and systemic), oxidative stress and protease-antiprotease 
imbalance.  They do not constitute clearly separated entities but are integrally related 
with each other. 
1.4.1 Lung inflammation 
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Inflammatory cells.  Lung inflammation in COPD affects the small and central 
airways, the lung parenchyma and the pulmonary arteries.  Cigarette smoke 
inhalation triggers an inflammatory reaction affecting the whole lung without 
necessitating established airflow limitation that includes neutrophils, macrophages, T-
lymphocytes, eosinophils and mast cells (O’Donnell et al., 2006).   
The airflow limitation that characterizes COPD succeeds cellular and structural 
changes of the airways and the inflammatory response triggered by cigarette smoke 
affects the entire tracheobronchial tree (central and peripheral airways, lung 
parenchyma and pulmonary arteries). In early stages, the walls of the central airways 
of smokers are infiltrated by macrophages, T-lymphocytes and low numbers of 
neutrophils while the latter ones are increased in the lumen. In the peripheral airways 
(respiratory bronchioles) the infiltrate of the walls consists of macrophages and 
mononuclear cells. As the inflammation progresses and COPD is established, the 
numbers of macrophages, T-lymphocytes in the walls as well as that of neutrophils in 
the lumen, are further increased (Keatings et al., 1996; Saetta et al., 1993).  
Furthermore, the ratio of CD4+/CD8+ T-lymphocytes is shifted towards the CD8+ 
which infiltrate the airway walls, parenchyma and the adventitial layer of the 
pulmonary arteries  (O’Shaughnessy et al., 1997; Saetta et al., 1999). 
 
Neutrophils. Two leukocyte-endothelial adhesion molecules, E-selectin and 
ICAM-1 expressed as ligands for leukocytes cell receptors are involved in the 
recruitment of neutrophils in sites of inflammation in the lung.  ICAM-1 serves as a 
ligand for CD11b/CD18 whose expression is increased in neutrophils of subjects with 
a rapid FEV1 decline. Their expression is upregulated by cytokines produced by 
macrophages, such as IL-1β and TNF-α.  Other neutrophil chemotactic factors are IL-
8, LTB4 and CCL5.  The recruited neutrophils adhere to the endothelial cells and 
then migrate into the lung where they secrete serine proteases (neutrophil elastases, 
cathepsin G and proteinase-3) and matrix metalloproteinases (MMP-8 and MMP-9).  
Although these molecules could play a role in the alveolar destruction process, the 
negative correlation between the numbers of neutrophils and the degree of 
destruction (Finkelstein et al., 1995) and the fact that in diseases with more 
pronounced neutrophilia, elastolysis is not a main feature, suggests that neutrophils 
do not play an integral part in the generation of emphysema (Barnes, 2004). These 
secreted molecules are secretagogues and serve in the role of neutrophils localized 
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in the bronchial glands of COPD patients in the development of mucus 
hypersecretion and airflow obstruction. Neutrophils localized in the smooth muscle of 
peripheral airways of COPD patients along with CD8+ lymphocytes further worsen 
the observed airflow limitation (Baraldo, 2004). 
 
Macrophages. Macrophages along with neutrophils are the two main cell types 
which produce elastolytic enzymes in the airways of smokers.  But macrophages are 
the most abundant cells in airway lavage under normal conditions and chronic 
inflammation (Kuschner et al., 1996; Linden et al., 1993).  During smoke exposure 
there is a 5- to 10-fold increase in the numbers of cells in BALF out of which 
macrophages constitute 98%  (Merchant et al., 1992; Shapiro, 1994) and after 
careful quantification a 25-fold increase in macrophage numbers was observed in 
tissue and alveolar space  (Retamales et al., 2001). Macrophages are recruited with 
the involvement of MCP-1 and its receptor CCR2 in the airway epithelium  (de Boer 
et al., 2000) and they localize in sites of alveolar wall destruction in emphysematous 
lungs  (Finkelstein et al., 1995; Meshi et al., 2002). The severity of COPD correlates 
to the numbers of macrophages in the airways  (Di Stefano et al., 1998).  
Macrophages participate in both the inflammation and emphysema by secreting 
inflammatory proteins and exhibiting elastolytic activity, a behavior enhanced in 
COPD patients and further increased by cigarette smoke exposure  (Lim et al., 2000; 
Russell et al., 2002a). Macrophages release reactive oxygen species, destructive 
extracellular matrix proteases, inflammatory cytokines and chemotactic factors, 
mucus gland activators and smooth muscle constrictors. The transcription factor NF-
κΒ in activated macrophages from COPD patients is the key regulator of most of the 
macrophage–produced inflammatory proteins  (Birrell et al., 2008; Caramori et al., 
2003; Di Stefano et al., 2002; Kent et al., 2008; Kersul et al., 2011; Li et al., 2012; 
Winkler et al., 2012). Included in the extracellular matrix proteases are at least 20 
proteolytic enzymes, the matrix metalloproteinase enzymes (MMPs) that hold a key 
role in tissue remodeling and repair during development and inflammation.  They 
break down collagen, laminin and elastin (McCawley and Matrisian, 2001).  The 
family members share a 40-50% similarity in amino acids and contain similar 
structural domains. Their classification according to their substrate specificity and 
amino acid similarity is shown in Table 1 (Visse and Nagase, 2003): 
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Table 1. Classification of Matrix Metalloproteinases (MMPs) according to their 
substrates. 
Subclass of MMPs MMPs 
collagenases MMP-1, MMP-8, MMP-13 
gelatinases MMP-2, MMP-9 
stromelysins MMP-3, MMP-10, MMP-11 
membrane-type MMP MMP-14 to MMP-25 
matrilysin MMP-7 
macrophage metalloelastase MMP-12      
 
They are secreted as inactive pro-enzymes and are activated either on the cell 
membrane surface or the extracellular space by enzymatic cleavage of their N-
terminal domain. Their activity depends upon the disruption of the interaction 
between an active site zinc ion and a cysteine residue in the prodomain (activation ) 
or the formation of a complex on the C-domain of the pro-MMP with a protein of the 
family of the tissue inhibitors of MMPs (TIMPs, 1 to 4), also produced by 
macrophages. The inhibition of MMPs by the different TIMPs is shown in Table 2 
(Brew and Nagase, 2010).  
Table 2. Tissue Inhibitors of MMPs and their effect on MMPs 
TIMP TIMP-1 TIMP-2 TIMP-3 TIMP-4 
MMPs or 
proMMPs 
inhibited 
MMP-14, 
MMP-16, 
MMP-19, 
MMP-24,  
Pro-MMP-9 
All MMPs,  
Pro-MMP-2 
All MMPs, 
Pro-MMP-
9, Pro-
MMP-2 
Most 
MMPs, 
Pro-MMP-
2 
 
In the case of COPD, the two most important MMPs are MMP-9 and MMP-12 
as they are responsible for the greater part of the elastolytic activity of macrophages. 
Several cytokines, mediators, surface molecules (HME, LPS, PMA, ConA, IL-6, IL-
1β, TNF-α, α5β1integrin, MMPSF, APMA, EDTA, alpha 2-macroglobulin, TPA, IL-1 
and epidermal growth factor) (Belaaouaj et al., 1995; Brew and Nagase, 2010; 
Busiek et al., 1992; Gomez et al., 1997; Leber and Balkwill, 1998; O’Keefe et al., 
1998; Visse and Nagase, 2003; Watanabe et al., 1993; Xie et al., 1998) affect the 
secretion of MMP-9. It has been demonstrated that the equilibrium between TIMPs 
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and MMPs is a mechanism that determines the progression of COPD itself (Ohnishi 
et al., 1998; Shapiro, 1994; Vignola et al., 1998). A particular case of interest is the 
relation between TIMP-1 and MMP-9 and how IL-10 produced by activated 
macrophages affects it. In healthy subjects IL-10 results in increased production of 
TIMP-1 and decreased production of MMP-9 while the situation is reversed in 
smokers with established emphysema where the increase of MMP-9 appears to be 
an early feature of the disease  (Abbal et al., 1998; Finlay et al., 1997; Lim et al., 
2000; Martinez et al., 1997; Mautino et al., 1999; Robinson et al., 1996).  
In addition to its elastolytic activity, MMP-12 is also involved in the recruitment 
of neutrophils in the lung through the release of TNF-α and upregulation of VCAM-1 
(Churg et al., 2002; Churg et al., 2003; Dhami et al., 2000; Murugan and Peck, 2009) 
or the fragmentation of elastin that acts as a chemoattractant for monocytes through 
the interaction with the elastin-binding protein (Kelly et al., 1987). It is also involved in 
the degradation and inactivation of α1-AT (Gronski et al., 1997). Another MMP with 
great significance that has been involved in the pathogenesis of emphysema is 
MMP-1 which has also been shown to have increased expression in lungs of COPD 
patients compared to healthy controls  (D’Armiento et al., 1992; Fujita et al., 2001; 
Iizuka et al., 2005). Macrophages are also potentially involved in the resistance to 
corticosteroid treatment due to reduced HDAC activity through increased secretion of 
TNF-α and IL-8  (Adcock et al., 2005; Barnes, 2006; Barnes, 2010; Mizuno et al., 
2011; Sundar et al., 2013). Finally, macrophages as neutrophils could theoretically 
be involved in mucus hypersecretion through the activity of IL-1 and LTB4. 
 
1.4.2 Protease/anti-proteinase balance 
The hypothesis that an imbalance between proteases and anti-proteases may be an 
integral part of the pathogenesis of emphysema and consequently of COPD has 
been based on the observations that α1-AT in humans and studies performed with 
the intratracheal instillation of elastases in animals leads to the development of 
emphysema (Churg et al., 2003; Hautamaki et al., 1997; Senior et al., 1977; Shapiro 
et al., 2003). This imbalance leads to the breakdown of several connective tissue 
components particularly elastin which is an important target for these enzymes.  This 
results in a loss of elasticity of the lung parenchyma.  Elastin is secreted by several 
cell types as tropoelastin, a precursor.  Monomers of tropoelastin in the extracellular 
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space form elastin polymers by cross linking under the action of lysyl oxidase.  These 
cross-links are known as desmosines and have served as evidence of elastin 
degradation  (Harel et al., 1980).  Studies have demonstrated that the excretion of 
desmosine is increased in smokers with a rapid decline in lung function  and there is 
a positive correlation between the annual rate of decline in FEV 1 and desmosine 
levels in the urine (Gottlieb et al., 1996). In animals challenged with an intratracheal 
instillation of elastases lung elastin is quickly depleted and the elastin content is 
restored yet the architecture is abnormal and resembles to the elastic fibers of 
human patients with emphysema (Goldstein and Starcher, 1978; Kuhn et al., 1976). 
A study evaluating BALs from COPD patients reported a direct correlation between 
NE burden and an inverse correlation with antielastase activity in emphysema (Fujita 
et al., 1990), supporting further the protease/antiprotease imbalance hypothesis. 
Although many proteases that break down elastin have been implicated in this 
process (Stockley and Campbell, 2001), neutrophil elastase has been of great 
interest due to the observations that patients with α1-AT develop early onset 
emphysema, the results from animal models of emphysema using neutrophil 
elastase (Janoff et al., 1977; Senior et al., 1977) and its localization on elastin fibers 
and emphysematous lungs (Damiano et al., 1986). While α1-AT inhibits neutrophil 
elastase, the alveolar macrophage elastase remains active and degrades elastin 
(Chapman and Stone, 1984; Chapman et al., 1984). However, α1-AT is ineffective in 
inhibiting NE already bound to elastin (Morrison et al., 1990). Smokers exhibit a 
reduction of about 40% α1-AT function when compared to non-smokers (Gadek et 
al., 1979).  However the decrease of activity in BALF was temporary and non-
significant 1 hour after smoking (Abboud et al., 1985). The mechanism of α1-AT 
functional inactivation is the oxidation of methionine in its active site (Carp et al., 
1982; Gadek et al., 1979). The reduction of activity of anti-elastase activity by smoke 
is also complemented by the recruitment of increased number of neutrophils that in 
turn secrete NE. The severity of the emphysema correlates to the increase of NE 
(Kidokoro et al., 1977). Neutrophil elastase is a serine protease with multiple 
functions and properties: 
 Degrades elastin. 
 Is stored in azurophilic granules of neutrophils. 
 Is expressed on the surface of cells primed by cytokines. 
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 Induces the expression of MUC5AC through a mechanism dependent on the 
generation of ROS. 
 Is a potent secretagogue and induces hypersecretion of mucus by 
submucosal and gland cells, a property inhibited by some antibiotics like 
erythromycin (Goswami et al., 1990) and flurithromycin (Gorrini et al., 2001). 
 Renders macrophages incapable of clearing apoptotic cells (including 
neutrophils) by cleaving the phospatidylserine receptor on their surface. 
 Increases the inflammatory response to endotoxin by the inactivation of CD14 
(receptor for LPS). 
 Its inactivation in mice increases their susceptibility to infections.  
Other proteases. 
Other serine proteases: Cathepsin G and  Proteinase 3 are also stored in 
neutrophilic granules and have similar properties to those of NE (Sommerhoff et al., 
1990; Witko-Sarsat et al., 1999). Cathepsins B, C, D, H, L and S may also contribute 
to emphysema (Reilly et al., 1989; Reilly et al., 1991; Shi et al., 1992; Turk et al., 
2001). They are overexpressed in mouse lungs when interferon gamma is inducibly 
targeted (Chapman et al., 1997; Wang et al., 2000). Alveolar macrophages from 
COPD patients secrete more cysteine proteases than healthy smokers or non-
smokers do (Russell et al., 2002b). 
Metalloproteases. 
Metalloproteases include MMPs, A disintegrin and metalloproteases (ADAMs), 
and ADAMs with thrombospondin motifs (ADAMTS). They serve in the modulation of 
tissue structure and function under both normal and pathological conditions and are 
involved in intracellular communication, cell differentiation during embryogenesis and 
development and tissue remodeling after injury (Flannery, 2006; Malemud, 2006). 
Pro-inflammatory cytokines like IL-6, TNF-α, IL-4 and IL-13 and inhibitors like TIMPs 
and a-2M regulate their function. As mentioned before, the fragmented elastin fibers 
also have a pro-inflammatory property and serve as chemoattractants for monocytes 
(Houghton et al., 2006; Hunninghake et al., 1981; Senior et al., 1980).  
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Table 3 summarizes (Barnes, 2004; Hayashi et al., 1996; Lagente et al., 2005; 
Nénan et al., 2005; Newby, 2006; Risinger et al., 2006; Yu and Stamenkovic, 2000) 
the main characteristics of the most important MMPs involved in the pathogenesis of 
COPD. 
 
Table 3. The main MMPs involved in the pathogenesis of COPD. 
MMP Source Substrate Additional function 
MMP-12 Alveolar macrophages Elastin Pro-inflammatory 
MMP-9 Alveolar macrophages, 
bronchial epithelial cells, 
mast cells, eosinophils and 
neutrophils 
Elastin, collagen IV, 
V, VII, X, gelatin, 
pro-MMP-9 and pro-
MMP-13 
Activation of  the 
latent TGF-β and IL-
8 
MMP-1 Alveolar macrophages, 
alveolar epithelial type II 
and bronchial epithelial 
cells 
Collagen I, II, III, IV, 
X 
Activation of  pro-
MMP-9 and pro-
MMP-2 
MMP-2 Bronchial epithelial and 
airway smooth muscle cells 
Collagen I, II, III, IV, 
VII, X, XI, XIV, 
elastin, fibronectin, 
gelatin 
Regulation of smooth 
muscle cell 
proliferation 
 
Abbreviations: MMP: matrix metalloproteinases, TGF-β: transforming growth factor beta, IL-8: 
interleukin 8. 
 
It has also been demonstrated that some MMPs interact with their respective 
inhibitors or those of others and this interaction can further worsen the reaction to 
cigarette smoke as in the case of MMP-12 degrading α1-AT and NE degrading in 
turn TIMPs  (Shapiro et al., 2003). 
Since MMPs attack substrates either exclusively other than elastin or in 
addition to it, the studies focused on them have speculated that emphysema may be 
related to the degradation of the lung matrix as a whole and not only elastin (Churg et 
al., 2012).  
 
1.4.3 Oxidative/nitrosative stress 
INTRODUCTION   
 17 
Oxidative stress is defined as “a disturbance in the pro-oxidant/antioxidant 
balance in favor of the former, leading to potential damage” (Sies 1985, 1986). Once 
the inflammatory cells are recruited in the air space they are activated and generate 
reactive oxygen species (ROS) and reactive nitrogen species (RNS).  Activated 
macrophages, neutrophils and eosinophils generate O2
─ which is then converted into 
H2O2 under the catalytic action of SOD and can then react to ∙OH in the presence of 
Fe2+.  ROS are also produced intracellularly mainly through the NADPH oxidase 
system and mitochondria (Macnee, 2006). Cigarette smoke contains high 
concentrations of oxidants and free radicals. The O2
─ and NO of the gas phase of 
cigarette smoke react quickly to a form the highly reactive peroxynitrite.  Due to its 
great diffusion coefficient peroxinitrite can cause greater damage in the tissues 
around its site of production.  Radicals of the tar phase react rapidly with molecular 
oxygen in a redox-dependent manner to form O2
─, ∙OH and H2O2.  
COPD patients exhibit higher levels of oxidative and carbonyl stress markers 
like nitrotyrosine, hydrogen peroxide, carbon monoxide, myeloperoxidase (MPO) 
(Ichinose et al., 2000; Montuschi et al., 2001; Paredi et al., 2000). 
Oxidative stress can stimulate the release of inflammatory chemotactic factors 
like IL-8 in the lungs of smokers (Gilmour et al., 2003), activate the NF-kB pathway, 
and directly damages  protein (carbonylation), lipids (peroxidation), carbohydrates 
and DNA (Aoshiba et al., 2012; Wistuba et al., 1997). 
This increased release of ROS from peripheral neutrophils and monocytes 
depletes the antioxidant firewall in patients with COPD in both plasma and lungs.  
Antioxidants such as GSH uric acid ascorbic acid have been found to be reduced in 
smokers.  In the case of GSH, cigarette smoke inhalation results in the formation of 
GSH conjugates in the airways that leads to an antioxidant deficiency and an 
injurious lung response.  Oxidative stress also leads to autophagy for the removal 
and degradation of damaged mitochondria and oxidized proteins as a defense 
mechanism.  However, excessive autophagy finally leads to cell death. 
Nevertheless, while ROS were initially from their discovery considered 
harmful, they have also been shown to act as messaging molecules, participating in 
signal transduction. Studies have demonstrated that ROS production after ligand 
binding of growth factors as PDGF and EGF is necessary for the physiological  
tyrosine kinase signaling by altering the phosphatase-kinase balance (Bae et al., 
1997; Sundaresan et al., 1995) or that they play a role in enzymatic activation (Guo 
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et al., 2010). These types of ROS effects indicate a role in the regulation of 
intracellular signaling pathways. 
1.4.4 Apoptosis 
“Apoptosis” is a Greek word that means “to fall/drop of” (απόπτωσις, 
από=of/from, πτώσις=falling). It is the term used to describe the morphological 
changes in a complex and tightly regulated process of programmed cell death. These 
changes include cell shrinkage, nuclear condensation, blebbing of the membrane, 
fragmentation into membrane bound apoptotic bodies and changes of the membrane 
that lead to phagocytosis of the cell that undergoes cell death (Kerr et al., 1972; 
Wyllie et al., 1980).   
Apoptosis has the opposite effect of cell division. However, it complements the 
latter in the homeostasis of cell populations and allows the elimination of unwanted, 
heavily damaged or infected cells. The various stimuli that trigger apoptosis are direct 
induction by immune cells, activation of death receptors, growth factor deprivation, 
loss of contact with the extracellular matrix and various heavy damages caused by 
stress. There are three main apoptotic pathways: 
1) the extrinsic pathway. It is triggered by extracellular signals, namely death 
ligands like the TNF, FasL and TRAIL that bind to their receptors on the cell surface 
(Strasser et al., 2000). The receptors are then multimerized and form the death 
inducing signaling complex (DISC) that contains adaptor molecules like the Fas 
associated death domain (FADD). This results in the cleavage of pro-caspase-8/10 
into their active forms, caspase-8/10 (Muzio et al., 1996; Muzio et al., 1998) that 
exhibit a protease activity and cleave specific substrates and start activating other 
caspases (3, 6, 7) (Hirata et al., 1998; Scaffidi et al., 1998) that finally cause DNA 
fragmentation (Tang and Kidd, 1998).  
2) the intrinsic pathway. It is mainly triggered by processes that cause DNA 
damage, like oxidative stress (Roos and Kaina, 2006; Roos and Kaina, 2013). This 
leads to the activation of tumor suppressor p53 routes which induces cell cycle 
associated (like p21,14-3-3σ) or apoptosis-related (Bax, NOXA, PUMA, Fas) gene 
transcription. If the DNA damage was severe enough these factors will translocate to 
the outer membrane of mitochondria where channels that allow pro-apoptotic factors 
like DNAase, cytochrome-C and anti-apoptotic factors inhibitors to move to the 
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cytoplasm. Consequently the apoptosome (cytochrome-C, Apaf-1 and caspase-9) is 
formed (Li et al., 1997; Liu et al., 1996; Zou et al., 1997) and caspase-9 is activated 
which in turn activates caspase-3 and initiates apoptosis (Slee et al., 1999).  
3) the endoplasmatic reticulum pathway, is triggered by cell signals such as 
hypoxia and apoptosis is induced through caspase-7-mediated caspase 12 (Rao et 
al., 2001; Szegezdi et al., 2003) activation.  
In human studies increased apoptosis has been demonstrated in several lung 
structural cells: endothelial cells (Imai et al., 2005; Kasahara et al., 2001; Segura-
Valdez et al., 2000; Yang et al., 1996), alveolar epithelial cells (Imai et al., 2005; 
Kasahara et al., 2001; Segura-Valdez et al., 2000; Yang et al., 1996; Yokohori et al., 
2004), interstitial cells (Segura-Valdez et al., 2000), inflammatory cells (Segura-
Valdez et al., 2000), mesenchymal cells (Imai et al., 2005), airway epithelial cells and 
BAL T-cells (Hodge et al., 2005). The samples in these studies came from lung 
tissue sections or BALs from emphysema or COPD patients. In addition, the pro-
apoptotic factors (Bax, Bad) were detected in emphysema patients but not in controls 
(Imai et al., 2005), and expression of VEGF and VEGFR2 mRNA and protein were 
significantly reduced in emphysema (Kasahara et al., 2001). Another study has 
shown decreased VEGF levels in induced sputum from COPD with severity of the 
disease (Kanazawa and Yoshikawa, 2005). 
In COPD patients the phagocytosis of apoptotic airway epithelial cells by 
alveolar macrophages is decreased compared to controls (Hodge et al., 2003). The 
mechanism behind this is the cleavage of the phospatidylserine receptor on 
macrophages by neutrophil elastase secreted by activated neutrophils (Keatings et 
al., 1996; Lacoste et al., 1993; Vandivier et al., 2002). Furthermore, the increased 
numbers of CD8+ cells in the lungs of COPD patients (Saetta et al., 1998; Saetta et 
al., 1999) are able to induce apoptosis through perforins (Barry and Bleackley, 2002; 
Liu et al., 1999). Neutrophil elastase has also been shown to induce apoptosis of 
small airway and alveolar epithelial cells via the intrinsic pathway and decreasing 
AKT phosphorylation (Suzuki et al., 2005). Α1-AT also can inhibit active caspases 
and consequently apoptosis of lung endothelial cells exposed to smoke (Aldonyte et 
al., 2008) and staurosporine (Petrache et al., 2006). The MMPs also might be 
involved in apoptosis since the Fas ligand is their (MMP-7) substrate  (Kayagaki et 
al., 1995; Powell et al.). Apoptotic lung epithelial cells have exhibited elastolytic 
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activity in an emphysema model in mice (Aoshiba et al., 2003). Apoptosis is also 
linked to oxidative stress. In a rat model of emphysema induced by VEGF receptor 
blockade, apoptosis was increased in areas of the lung where oxidative stress was 
present while the oxidative markers were reduced after the blockade of apoptosis 
(Tuder et al., 2003). Mice exposed to smoke for a period of 6 months showed 
enhanced alveolar oxidative stress; and increased number of apoptotic alveolar 
septal cells when compared to wild type mice (Rangasamy et al., 2004). Oxidative 
stress is also associated with reduced levels of VEGF in sputum of COPD patients 
(Kanazawa and Yoshikawa, 2005). 
1.5 COPD in other animal species. 
Pathological conditions similar to COPD are also seen in other animal species, 
most prominently in horses and small companion animals (dogs and cats) with 
respective differences in etiology, pathophysiology, symptomatology and treatment. 
In horses, COPD is now referred to as recurrent airway obstruction (RAO) or 
with its more empirical name “heaves”. It constitutes the most common cause of 
chronic cough in this animal species. Other clinical manifestations are exercise 
intolerance and in more severe cases expiratory dyspnea. Susceptible (genetically 
predisposed) horses exposed to airborne agents most notably organic dust 
containing molds (Aspergillus fumigatus, Faenia rectivirgula, Thermoactinomyces 
vulgaris) (Séguin et al., 2010; Séguin et al., 2012), bacterial endotoxins, proteases 
among others, found in the housing stables and the hay used for feeding, develop 
the disease. In the stables horses can also be exposed to high levels of gases such 
as ammonia that also contribute to the induction of the disease. Removal of the 
animals outdoors or in stable with less dust burden can cause remission but the 
disease may persist either due to irreversible structural alterations (Kaup et al., 1990) 
or to mild airway inflammation (Bureau et al., 2000). RAO affects a considerable 
number of horses in Great Britain (14%) (Hotchkiss et al., 2007). While the 
immunological mechanism of the disease is not fully understood, and the clinical 
symptoms show similarities with human asthma, RAO is a much more complex 
condition than an allergy. The pathophysiology of the disease presents several 
discrepancies with asthma. For example in the BALF of affected horses it is 
neutrophils that predominate (Art et al., 2008) and there is absence of increased 
histamine levels (McGorum et al., 1993), while additionally a delayed bronchospasm 
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occurs after antigen challenge (Deaton et al., 2007).  T-lymphocytes and epithelial 
cells play a central role in the pathogenesis of the disease by recruiting neutrophils 
into the airways.  These cells along with macrophages most likely produce MMPs 
(MMP-1, MMP-8, MMP-9, MMP-13) (Nevalainen et al., 2002; Raulo et al., 2001).  
Finally, the structural changes of the small airway walls associated with bronchiolitis 
lead to airway obstruction.  This obstruction commonly leads to emphysema, 
predominantly of the distensive type (Marinkovic et al., 2007). 
In dogs and cats chronic bronchitis (CB) results in a chronic cough for more 
than two months that cannot be attributed to other causes like chronic heart failure, 
bronchopneumonia or pulmonary neoplasia.  The disease more commonly affects 
small or toy, older and overweight dogs, although it can also be reported in larger 
breeds  (Rozanski, 2014). The cough is typically dry, non-productive that mostly 
occurs after excursion (exercise intolerance) or at night produced by secretion 
accumulation.  The animals are also presented with wheezing, abdominal push, 
crackles during auscultation, cyanosis and even syncope in severe cases (Johnson, 
2008).  Irritation of the trachea also leads to coughing.  The most common etiological 
factors are recurrent airway inflammation from infections or irritant inhalation.  
Glandular hypertrophy and goblet cell hyperplasia lead to increased mucus 
production.  Epithelial edema, thickening and metaplasia lead to airway narrowing. In 
more advanced cases mild emphysema is also present, making the condition more 
similar to the human disease. However dogs do not present clinical signs of 
emphysema (Johnson, 2006). 
1.6 Sestrin 2 
Sestrin 2 belongs to a family of highly conserved proteins that are ∼48-60 kDa 
in size. Mammalian cells express 3 sestrin isoforms: i) sestrin 1 (SESN1 or PA26), ii) 
sestrin 2 (SESN2 or Hi95) and iii) sestrin 3 (SESN3). Sestrins were initially 
discovered via subtractive cDNA cloning experiments to identify p53 target genes 
(Velasco-Miguel et al., 1999) (sestrin 1) and hypoxia upregulated genes (sestrin 2 
and sestrin 3); after attention was drawn to p53 and its mutations and/or inactivation 
in cancer (Budanov et al., 2010). Sestrin 2 was discovered 2 years (2001) later than 
sestrin 1 as a close homologue of the latter. The name of the protein family comes 
from Sestri Levante, a town located in the Italian Riviera where, during a human 
genetics course, the high amino sequence homology between the 3 family members  
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(Budanov et al., 2004) was discovered (Peeters et al., 2003). The sestrin 2 gene is 
located on chromosome 4 in the mouse and chromosome 1p35.3 in humans. 
Their role is believed to be the regeneration of peroxiredoxins (Prxs), a family 
of thiol-containing peroxidases that catalyze the destruction of endogenously 
produced peroxides in eukaryotes (Seaver and Imlay, 2001) and decompose RNS 
(Barr and Gedamu, 2003; Bryk et al., 2000; Chen et al., 1998; Wong et al., 2002), 
even though that is a matter of debate where sestrin 2 is concerned (Woo et al., 
2009). Peroxiredoxins are inactivated through an overoxidation of a reactive cysteine 
(peroxidatic cystein, Cys-SH) in their catalytic center (Rabilloud et al., 2002; Yang et 
al., 2002). Under conditions of high peroxide concentrations, Prxs are overoxidized 
and yield sulfinic acid (Cys-SO2H) and cannot be reduced by typical reductants like 
glutathione. Normally this peroxidatic cysteine is oxidized to sulfenic acid that forms a 
disulfide bridge with the resolving cysteine of the other subunit of the Prx dimer, 
which is consequently reduced by thioredoxin (Chae et al., 1994a; Chae et al., 
1994b; Woo et al., 2003). But the slow formation of the disulfide bridge allows further 
oxidation of the sulfenic acid to sulfinic acid (Cys-SO2H) that cannot be reduced 
(Wood et al., 2003). As a consequence Prxs become inactive and accumulate in the 
oxidative stress-exposed cells (Budanov et al., 2004). This mechanism allows 
peroxide, which acts as a signaling molecule, to convey its message to redox-
sensitive components of signaling pathways by inactivating peroxidase activity 
(Georgiou and Masip, 2003; Wood et al., 2003), an apparent evolutional advantage 
of eukaryotes that use peroxide for that purpose (Wood et al., 2003). While both 
sulfiredoxins (Srx) and sestrins have been reported to be responsible for this 
regeneration (Budanov et al., 2004; Chang et al., 2004), it was later demonstrated 
that neither sestrin 2 has the reductase activity of sulfiredoxin nor exists a sequence 
similarity between the two (Woo et al., 2009). The mechanism by which sestrin 2 
participates in the regeneration of Prxs was shown to be via the autophagic 
degradation of the Kelch-like ECH-associated protein 1 (Keap-1), a repressor of the 
antioxidant nuclear factor erythroid 2-related factor 2 (Nrf2) (Itoh et al., 2010), which 
then activates Srx (Bae et al., 2013). In conclusion, the antioxidant role of sestrin 2 is 
the promotion of the antioxidant Nrf2 signaling, which activates Srx among other 
target genes and finally leads to the regeneration of Prxs. 
Sestrins are also implicated in the mammalian target of Rapamycin (mTOR) 
inhibition via a p53-activation mechanism through a redox-independent manner 
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(Budanov and Karin, 2008). mTOR, a serine/threonine protein kinase that belongs to 
the PIKK (phosphatidylinositol kinase-related kinase) family and regulates cell growth 
and proliferation (Corradetti and Guan, 2006; Fingar and Blenis, 2004; Guertin and 
Sabatini, 2005; Hay and Sonenberg, 2004; Soliman, 2005; Thomas, 2006; 
Wullschleger et al., 2006), forms two distinct signaling complexes: i) mTORC1 
(mTOR along with raptor, PRAS40 and mLST8) that regulates cell growth and 
protein synthesis (Guertin and Sabatini, 2005; Yang and Guan, 2007), and ii) 
mTORC2 (mTOR with rictor, sin1, Protor-1 and mLST8) that regulates the actin 
cytoskeleton and cell spreading (Astrinidis et al., 2002; Sarbassov et al., 2004; Yang 
and Guan, 2007). mTORC1 phosphorylates the S6K1 and 4E-BP-1 to enhance 
translation within the ribosomal translation initiation complex and cap-dependent 
mRNA translation respectively (Choi et al., 2003; Nojima et al., 2003; Schalm and 
Blenis, 2002; Wullschleger et al., 2006). The mTOR signaling pathway has been 
shown to have several upstream regulators: growth factors (Ma et al., 2005; Potter et 
al., 2002; Roux et al., 2004), hypoxia (Arsham et al., 2003; Brugarolas et al., 2004; 
Hudson et al., 2002), ROS (Bae et al., 1999; Sarbassov and Sabatini, 2005; Smith et 
al., 2005), etc., including sestrin 2 (Budanov and Karin, 2008). Sestrin 2 is a potent 
inhibitor of mTOR through the TSC1:TSC2 complex via stimulation of AMPK, a major 
TSC2 kinase and by phosphorylation of TSC2 which also depends on AMPK 
(Budanov and Karin, 2008). mTOR acts as a crucial regulator of cell growth and 
proliferation but also exerts anti-inflammatory (Säemann et al., 2009; Weichhart et 
al., 2008; Weichhart et al., 2011) and angiogenic effects (Advani, 2010). 
As p-53 target genes, sestrins participate in protection of cells from various 
insults.  Under normal physiological conditions, sestrins offer a baseline protection 
from any damage resulting from processes like respiration and DNA replication. 
Under genotoxic stress and DNA damage save energy that can be directed towards 
DNA repair by minimizing new protein and membrane synthesis through attenuating 
TORC1 activity via AMPK activity enhancing, that leads to inhibition of anabolic 
pathway also resulting in arrest of lipid and protein synthesis. This also inhibits 
proliferation and promotes the removal of cells with DNA damage. Under oxidative 
stress, the induction of sestrin transcription results in ROS scavenging and 
peroxiredoxins regeneration and furthermore, through the inhibition of TORC1, in 
damaged mitochondria elimination (Jin, 2006). An additional effect of TORC1 
shutdown is the improvement of mitochondrial respiration and the reduction of ROS 
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production (Bonawitz et al., 2007). Finally in hypoxic conditions, the TORC1 inhibition 
by sestrin counteracts apoptosis and once more saves energy for the cells to adapt.  
These effects of sestrin 2 activation are summarized in Fig. 1. 
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Figure 1. Outline of sestrin 2 functions under stress and normal conditions. 
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Besides mTOR, sestrin 2 has been implicated in pulmonary emphysema by 
regulating the TGF-β pathway, also involved in tissue remodeling and regeneration. 
Sestrin 2 mutational inactivation partially rescued the emphysema phenotype in a 
mouse model (Ltbp4S-/- mice), an effect correlated with the upregulation of TGF-β 
and mTOR pathways. In addition the effect of sestrin 2 inactivation on mTOR is TGF-
β- and not redox-dependent (Wempe et al., 2010).  
Furthermore, sestrin 2 silencing increases PDGFRβ expression in human 
glioblastoma U87 cells and results in PDGFRβ accumulation due to slow degradation 
(Liu et al., 2011). A similar upregulation has been demonstrated in mouse embryonic 
fibroblasts lacking peroxiredoxin II (PrxII) (Choi et al., 2005) which theoretically 
requires sestrin 2 for its regeneration in some cellular contexts. PDGF is a potent 
mitogen and chemoattractant involved in the recruitment of mesenchymal cells 
(Betsholtz, 2004) and wound repair  (Gao et al., 2005). PDGFRβ is a tyrosine kinase 
that has five immunoglobulin domains extracellularly and a split tyrosine kinase 
domain in the cytoplasm. Binding of the ligand to the receptor leads to receptor 
dimerization and activation of the tyrosine kinase domains. This leads to 
autophosphorylation of several tyrosine residues in the cytoplasmic domains of the 
receptor and the creation of docking sites for several signaling proteins and adaptors 
(Heldin and Westermark, 1999). After activation the receptor is internalized and 
either degraded in lysosomes or recycled back to the cell surface for reuse. Most cell 
types do not express simultaneously the ligand and the receptor, indicating a 
paracrine mode of action. However, fibroblasts and vascular smooth muscle cells 
express both, making an autocrine action possible. PDGFRβ participates in 
embryonic development while in the adult it mainly plays a central role in wound 
healing. Activation of the PDGFRβ receptor regulates important processes such as 
ECM production proteins crucial in repair and angiogenesis through controlling of the 
differentiation of fibroblasts into myofibroblasts and vascular smooth muscle cell and 
pericyte recruitment and proliferation respectively (Abramsson et al., 2003; Betsholtz, 
2004; Gao et al., 2005). PDGFβ and PDGFRβ null mutants die near birth from 
widespread hemorrhages (Levéen et al., 1994; Soriano, 1994) due to diminished 
numbers of vascular smooth muscle cells and pericytes. During embryonic 
development, PDGFβ/PDGFRβ signaling seems to participate in the induction of 
proliferation of these types of cells during their recruitment to new vessels where they 
express the receptor and the sprouting epithelium expresses the ligand. In the null 
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mutants the new vessels are unable to attract pericytes which serve to support the 
vessel wall and control the formation of normal diameter and function (Betsholtz, 
2004). Thus the newly formed capillaries are weak and increased blood flow can lead 
to rupturing. Finally, PDGFRβ signaling plays an important role in all stages of wound 
healing where it participates in the recruitment of inflammatory cells immediately after 
injury (Heldin and Westermark, 1999; Trengove et al., 2000; Vogt et al., 1998), 
granulation tissue formation  (Uutela et al., 2004),  blood vessel maturation (Lindahl 
et al., 1997; Sundberg et al., 1997) and in the production by fibroblasts of ECM 
proteins necessary for tissue repair and remodeling (Jinnin et al., 2005; Lin et al., 
2006; Rhee and Grinnell, 2006).  
1.7 Emphysema models 
The two emphysema models used in the experiments conducted were the 
smoke-induced and elastase-induced emphysema in the mouse. While other rodent 
species (rats, hamsters, guinea pigs) have been used to model the disease, the 
mouse is the most favorable one for studying emphysema. Many reasons make this 
species an ideal choice: the mouse genome has been sequenced as well as the 
human one and only a few differences have been demonstrated (about 300 genes) 
between them (Waterston et al., 2002), a good knowledge of its anatomy and 
physiology, the variety of naturally occurring strains, extensive antibody availability, 
high reproductive turnover, short life span, low cost of maintenance and housing.  
1.7.1 Cigarette smoke-induced emphysema 
Since cigarette smoke is by far the most common cause of COPD in 
developed countries, it has been one of the most attractive experimental models to 
be used on a variety of animal species (guinea pigs, rabbits, dogs, rats, mice). The 
effectiveness of the model depends on numerous factors such as the mouse strain, 
type of exposure (whole-body chambers, nose-only exposure systems), type of 
smoke used (mainstream, side-stream), duration of exposure, smoke concentration, 
brand and number of cigarettes, sex and age of mice used in the experiments. In 
general, a smoke exposure of at least 6 to 8 months, 5-6 hours/day, 5 days/week will 
induce lesions in mice similar to those of a mild form of emphysema in humans 
(Guerassimov et al., 2004; Martinez et al., 2007; Takubo et al., 2002). Immediately 
after the beginning of cigarette smoke exposure neutrophils are recruited, 
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macrophages accumulate in tissue destruction occurs. Physiologically, the residual 
volume, functional residual capacity, total lung capacity and compliance are 
increased, flow decreases in the lower lung volumes (Wright et al., 2008). 
Histologically, goblet cell metaplasia occurs (Bartalesi et al., 2005), small airway 
walls are thickened (Bracke et al., 2006; Churg et al., 2006) (mostly collagen and 
fibronectin and not smooth muscle participates in this thickening), lymphocytes 
aggregate around the bronchioles (Bracke et al., 2006; Bracke et al., 2007). Smoke 
also produces vascular remodeling in this animal species (Nadziejko et al., 2007; 
Seimetz et al., 2011). In the end, this model produces a disease severity similar to a 
GOLD stage 1 or 2 (Wright et al., 2008). Although the underlying mechanisms 
between this animal model and human COPD may not all be identical, the smoke-
induced emphysema model is a useful tool for the investigation of cellular and 
molecular mechanisms involved in the development and progression of emphysema, 
while allowing to study the effects of the most common risk factor of COPD, cigarette 
smoke.  
1.7.2 Elastase-induced emphysema 
The intratracheal instillation of tissue-degrading enzymes has also been used 
to produce emphysema-like lesions. After the initial report of the early development 
of emphysema in α1-antitrypsin deficient patients (Laurell and Eriksson 1963) and 
the description of emphysema induction in rats by instillation of papain (Gross 1965) 
a lot of other studies followed that contributed to the formulation of the protease-
antiprotease hypothesis. Although numerous enzymes have been employed, the 
observation that only those that attack intact elastin can produce emphysema, led to 
the conclusion that the fundamental pathological abnormality was the destruction of 
the elastin framework. Most studies use porcine pancreatic elastase (PPE) or human 
neutrophil elastase (HNE). PPE is the most used, since it has produced the most 
consistent and impressive results (airspace enlargement), is easy to obtain and is 
much less expensive than HNE (Antunes and Rocco, 2011). Different protocols exist 
(single to repeated instillations of elastase, dose of elastase administered) but a 
single administration of elastase is adequate to produce emphysema-like lesions 
within 21 days in mice. The severity of the disease depends on the dose selected. 
Thus, it is possible to rapidly produce severe emphysema with this model. These 
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characteristics make the elastase-induced emphysema model a very useful tool in 
the investigation of new drug interventions.  
While the mechanism and basic principle on which this model works initially 
appears simple as a digestion of lung tissue by the enzyme, when the half-life of 
elastase was measured (Stone et al., 1988) it was found to be only about 50 minutes. 
Since an intervention with an inhibitor did not prevent progression, it is suggested 
that other processes are involved than just the enzyme activity of elastase bound to 
the matrix. Several elastase inhibitors and elastin protectors have only partially 
protected from emphysema (Cantor et al., 2000; Lafuma et al., 1991; Lungarella et 
al., 1986), suggesting a more complicated mechanism. The elastase instillation also 
leads to an inflammatory response involving cells and mediators (neutrophils, 
macrophages, TNF-α, IL-1b, IL-6,IL-8) (Gamze et al., 2007). It is also speculated that 
it can also mediate apoptosis (extrinsic pathway) through a TNF/TNFR interaction 
(Lucey et al., 2002). Additional evidence also suggests that the application of 
elastase acts not only as a mechanistic attack on elastin but involves abnormal repair 
of collagen (Hoffman et al., 2010; Ito et al., 2005; Kononov et al., 2001; Lucey et al., 
1998; Rubio et al., 2004).  
Elastase, depending on the instillation techniques, can produce more 
homogenously distributed lesions in the lung and produces panacinar emphysema, 
more closely related to genetic emphysema in humans, with lesions that are stable 
and do not regress like in the smoke model. Moreover, it also produces systemic 
effects similar to those seen in human COPD patients (Fournier and Lewis, 2000; 
Lüthje et al., 2009; Mattson et al., 2002; Supinski and Kelsen, 1982). Overall, while 
this model employs partially different mechanisms than the smoke exposure one and 
results should be extrapolated to human disease with caution, it is a very valuable 
screening technique for new interventions. 
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Figure 2. Macroscopic lesions of emphysema in mice lungs after PPE instillation.  
Left panel: control lung, right panel: emphysematous lung (0.6U of elastase, 3 weeks after instillation), 
(photographs taken from own experiments). 
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2. AIMS OF THE STUDY
The main objective of this thesis was to investigate sestrin 2 as a new possible 
therapeutic target for the treatment of COPD and its role in the development of 
emphysema. 
In this context, the smoke-induced emphysema model and the elastase-induced 
emphysema were employed to: 
1. Establish if the mutational inactivation of sestrin 2 would protect mice from 
developing smoke-induced emphysema/COPD.  
2. Elucidate the involvement of setrin 2 in disrupting alveolar maintenance 
programs in regards to PDGFRβ and mTOR signal transduction pathways. 
3. Determine whether PDGFRβ constitutes a central player in emphysema 
pathogenesis by employing the elastase-induced emphysema in 
combination with a PDGFRβ inhibitor (imatinib). 
4. Investigate whether PDGFRβ activation is ROS-dependent, since sestrin 2 
appears to contribute to the redox homeostasis. 
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3. MATERIALS 
3.1 Solutions and substances 
 Heparin: Heparin-Natrium-25000-ratiopharm®, B. Ratiopharm GmbH, Ulm, 
Germany 
 Ketamin hydrochloride 100 mg/ml, Ketamin 10%®, Belapharm GmbH & Co 
KG, Vechta, Germany 
 Xylazin hydrochloride, Xylazin 2%®, Ceva Tiergesundheit GmbH, Düsseldorf, 
Germany 
 Sterile physiological saline solution (for injections) Braun, Melsungen, 
Germany  
 Isoflurane Isofluran Baxter®, Baxter Germany GmbH, Unterschleißheim, 
Germany 
 Sodium chloride NaCl 0,9% Ecotainer®, Braun, Melsungen, Germany  
 Formaldehyde solution 3.5-3.7%, Otto Fischar GmbH & Co, Saarbrücken, 
Germany 
 50% 2 propanol, 1%povidone-iodine (10% available iodine), Braunoderm ®, B. 
Braun Melsungen, AG Melsungen, Germany 
 Isotonic saline, isotonic sodium chloride solution 0,9% Diaco ®, Serag-
Wiessner KG, Naila, Germany 
 Xylocain1%, AstraZeneca GmbH, Wedel, Germany 
 
In the elastase-induced emphysema experiment 
 Elastase: PPE, ET947, Elastin Products Company, Inc., Owensville, Missouri, 
USA 
 Elastase Substrate:Succinyl-Ala-Ala-Ala-pNitroanilide,NS945, Elastin Products 
Company, Inc., Owensville, Missouri, USA 
 Imatinib, Glivec® 400 mg, Novartis International AG, Basel. Switzerland 
 Tris HCL, Carl Roth GmbH & Ko, Karlsruhe, Germany 
 Tris, Carl Roth GmbH & Ko, Karlsruhe, Germany 
 Sodium acetate, NaOAc Carl Roth GmbH & Ko, Karlsruhe, Germany 
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3.2 Consumables 
 Syringes (single use): Inject® Luer Solo 0,001-1ml, 2ml, 5ml, 10ml, 20ml, 
Original Perfusor® Spritze 50ml, Braun, Melsungen, Germany 
 Needles (single use): BD MicrolanceTM 3, 24G 1” (0,55x25mm), 26G ½” 
(0,45x13mm), 30G ½” (0,3x13mm), Becton Dickinson, Heidelberg, Germany  
 Single use examination gloves NitraTex, Ansell, Munich, Germany 
 Eye cream, Bepanthen® Eye and Nose ointment, Bayer Vital Leverkusen, 
Germany 
 Medical adhesive bands Durapore® 3M St. Paul, MN, USA  
 Gauze balls (size 6), Fuhrman Verrbandstoffe GmbH, Much, Germany  
 i.v. catheter’s cannula used as a tracheal tube: Vasofix® Safety 22G 
Braunüle® Braun, Melsungen, Germany 
 Surgical sutures: a) Nr. 12 Coats GmbH, Kenzingen, Germany, b) non-
absorbable size 5-0 ETHIBOND EXCEL® Ethicon GmbH, Norderstedt, 
Germany, c) size 5-0, 6-0 and 7-0 ProleneTM, Ethicon GmbH, Norderstedt, 
Germany, d) Black merciful 100% cotton AMANN, Bönnigheim,Germany 
 Polyester Thread 5/0, FSSB, Jestetten, Germany 
 3-way stopcocks Discofix®-Braun, Melsungen, Germany  
 Closing cones: Combi-Stopper Intermedica GmbH, Klein-Winternheim, 
Germany 
 Perfusor-tubing 150 cm Perfusor-Line 150,Braun, Melsungen, Germany  
 Surgical instruments T.S.E., Berlin, Germany  
 Tubes for cryogenic transportation and storage of biological material, 
Cryo.s™, Greiner Bio-One GmbH, Frickenhausen, Germany 
 Eppendorf tubes, SafeLock 1,5ml, Sarstedt AG & Co, Nümbrecht, Germany 
 Glass capillary tubes for hematocrit, Hirschmann Laborgeräte GmbH & Ko 
KG, Eberstadt, Germany 
 Hematocrit-sealing kit, Brand GmbH & Ko KG, Wertheim, Germany 
 Pipettes: Eppendorf Eppendorf Vertrieb Deutschland GmbH, Wesseling-
Berzdorf, Germany 
 Pipette tips: 200μl,   1000μl,  Sarstedt, Nümbrecht, Germany 
 Falcon tubes: 15ml, 50ml Cellstar® Tubes, Greiner Bio-One GmbH, 
Frickenhausen, Germany 
 Parafilm Wrap  Bemis Flexible Packaging, Neenah WI, USA 
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 Scalpels: Feather® Disposal Scalpel No. 10, 11, Pfmmedical AG Köln, 
Germany 
 Paper Napkins: Tork, Mannheim, Germany 
 Micro-tubes 1.5ml, Sarstedt, Nümbrecht, Germany 
 
3.3 Hemodynamics–Lung Function setup 
 Centrifuge for hematocrit: Hematocrit 210, Hettrich Zentrifugen, Tuttlingen, 
Germany 
 Centrifuge Mikro 200R, Hettrich Zentrifugen, Tuttlingen, Germany 
 Mouse ventilator, MiniVent Type 845, Hugo Sachs Elektronik, Hugstetten, 
Germany 
 Tracheal tube, Vasofix® Safety, 20G shortened ca 1,5 cm, B. Braun 
Melsungen AG, Melsungen, Germany 
 Carotis catheter, Micro Cannulation System, FST Fine science tools GmbH, 
Heidelberg, Germany  
 Jugular catheter, Hyman Mouse Pressure Catheter 14 cm, Nu MED Inc. 
Hopkinton, USA 
 Software for lung function measurement, Pulmodyn W, Hugo Sachs 
Elektronik, Hugstetten, Germany 
 Lab bath circulator, Lauda E100 + Lauda MA6, Delran, New Jersey, USA  
 PET-Tubes Tygon®, Saint-Gobain Performance Plastics, Charny, France 
 Gauze 5 x 4 cm Purzellin® Lohmann und Rauscher, Rengsdorf, Germany 
 Gauze balls size 6 Fuhrman Verrbandstoffe GmbH, Much, Germany 
 3 way stopcock Discofix®-Braun, Melsungen, Germany 
 Computer with Labtech Notebook PC-Based Data Acquisition Software for 
Windows, OMEGA Engineering, INC., Stamford, Connecticut, USA 
 Transbridge TBM4M, Transducer Amplifier, World Precision Instruments, Inc, 
Berlin, Germany 
 Combitrans disposable transducer  for arterial blood pressure measurement 
Braun, Melsungen, Germany 
 DT BNC Box USB 9800 Series, Data Translation®, Hugo Sachs Elektronik 
Hugstetten, Germany 
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 Differential Pressure Transduser, MPX Typ 399/2, Hugo Sachs Elektronik 
Hugstetten, Germany 
 Blood analyzer ABL 330 Radiometer, Copenhagen, Denmark 
 
3.4 Histology 
3.4.1 Equipment 
 Dehydration machine: Fully Enclosed Tissue Processor TP1050, Leica 
Microsystems, Nussloch, Germany 
 Cassette & slide printer, Sakura, IDentTM, Alphen aan den Rijn, The 
Netherlands 
 Embedding center: heated paraffin embedding module Leica EG1140H / Cold 
plate for modular tissue embedding system Leica EG1150C, Leica 
Microsystems, Nussloch, Germany 
 Rotating Microtome: Fully automatic rotating microtome RM2165, Leica 
Microsystems, Nussloch, Germany 
 Waterbath for paraffin section, HI 1210, Leica Microsystems, Nussloch, 
Germany 
 Analytical balance, PL303 Mettler-Toledo GmbH,  Giessen, Germany 
 pH meter, Labor-pH-Meter 766, Knick GmbH & Co. KG, Berlin-Zehlendorf, 
Germany 
 Magnetric Stirrer, RH basic 2 IKAMAG®, IKA®-Werke GmbH & CO. KG, 
Staufen / Germany 
 Microscope slides drying table, Flattening table for clinical histopathology HI 
1220, Leica Microsystems, Nussloch, Germany 
 Incubator for drying histological slides, Memmert Oven 100-800, Memmert 
GmbH & Co KG, Schwabach, Germany 
 Image analysis workstation, Leica Q 550 IW, Leica Microsystems, Nussloch, 
Germany, comprised of: 
 Microscope, Leica DMLA, Leica Microsystems, Nussloch, Germany 
 CCD camera, Leica DC300F, Leica Microsystems, Nussloch, Germany 
 PC, T3500, Dell 
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 Image analysis software with appropriate macros for the necessary analyses 
(SeptaeAutoanalyze, Vascular muscularization, Cell counting), Leica Qwin, 
Leica Microsystems, Nussloch, Germany 
3.4.2. Consumables 
 Embedding cassettes: a) macro Rotilabo®, extra high 12mm, Carl Roth GmbH 
&Ko, Karlsruhe, Germany b) small, Tissue Tek® Uni-Cassette®, Sakura 
Finetek Europe B.V Zoeterwoude, Netherlands 
 Microscope glass slides, Superfrost Plus® - frosted white, R. Langenbrinck, 
Emmendingen, Germany 
 Coverslips, 24x36 mm, R. Langenbrinck, Emmendingen, Germany 
 Single use examination gloves Touch ‘n’ Tuff®, Ansell, Munich, Germany 
 Di-sodium hydrogen phosphate dehydrate, Merck, Darmstadt, Germany 
 Potassium chloride, ROTH, Carl Roth GmbH + Co, Karlsruhe, Germany 
 Sodium chloride, Sigma-Aldrich, Steinheim, Germany 
 Potassium dihydrogenphosphate, Merck, Darmstadt, Germany 
 Hydrogen peroxide 30% pro analysi Merck, Darmstadt, Germany  
 Ethanol 96%, 99.6% Otto Fischar, Saarbrücken, Germany 
 Ethanol 70%, SAV Liquid Production GmbH, Flintsbach, Germany 
 Isopropanol(≥99.8%), Methanol (≥99.8%), Sigma-Aldrich, Steinheim, Germany 
 Resorcin Fuchsin Chroma, Münster, Germany 
 Xylol Roth, Karlsruhe, Germany 
 Nuclear Fast red, Kernechtrot Aluminiumsulfate Chroma, Münster, Germany 
 Roti-Histol (Xylolersatz) Roth, Karlsruhe, Germany 
 Microtome blades: a) MX35 Premier, ThermoScientific, Dreieich, Germany, b) 
Leica 819, Leica, Leica Microsystems, Nussloch, Germany 
 Mounting medium, Pertex®, Medite GmbH, Burgdorf, Germany 
 
3.5 Smoke generation and exposure system 
 Smoke generator, Custom-made, Burghart Tabaktechnik GmbH, Wedel, 
Germany 
 Vacuum pump for smoke generator, Jun-Air, Ahrensburg, Germany 
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 Pump for smoke transfer to exposure chamber, TSE, Bad Homburg, Germany 
 Millipore filter, Millipore, Schwalbach, Germany 
 3R4F Standard cigarettes, University of Kentucky, Lexington,KY, USA 
 Computer program for monitoring smoke, TSE, Bad Homburg, Germany 
 
3.6 ROS measurements 
 Electron Spin Resonance (ESR) spectrometer, EMX micro Bruker, Karlsruhe, 
Germany 
 Superoxide dismutase–polyethylene glycol from bovine erythrocytes, Sigma-
Aldrich, Steinheim, Germany 
 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH), Noxygen 
Denzlingen, Germany 
 Tempol, R&D System GmbH, Wiesbaden-Nordenstadt, Germany 
 
3.7 Cell culture 
 
 Dulbecco’s modified Eagle’s medium (DMEM) - High Glucose, Sigma-Aldrich, 
Steinheim, Germany 
 10% fetal calf serum (FCS) 
 2  mM glutamine, Gibco, Invitrogen, Karlsruhe, Deutschland  
 1% penicillin/streptomycin, Gibco, Invitrogen, Karlsruhe, Deutschland  
 0.2 μm Millipore filter, Millipore, Schwalbach, Germany 
 cut-off filtration membrane, Vivaspin 20, Sartorius, Göttingen, Germany   
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4. METHODS 
4.1 Animals 
4.1.1 Approvals for the experiments 
All the experiments performed in the context of this study were carried out 
according to the EU Directive 86/609/EEC and the rules and regulations of the 
Justus-Liebig University of Giessen, and were approved by the Regierungspräsidium 
Giessen. The corresponding animal experiment approved proposals can be found 
under the references: GI 20/10, Nr.37/2011, entitled “Charakterisierung der Rolle von 
sestrin 2 bei der Entstehung des Zigarettenrauch-induzierten Lungenemphysems mit 
Hilfe transgener Mausmodelle” for the smoke-induced emphysema experiment and 
GI 20/10, Nr.28/2012, entitled “Rolle von sestrin 2 für die Entstehung des 
Lungenemphysems” for the elastase-induced emphysema experiment. 
4.1.2 Sestrin 2 KO mice 
All experiments in this study employed 8-10 week old male and female sestrin 
2 KO mice (RRJ141/Sesn2Gt(RRJ141)Byg) and C57BL/6J WT mice. The RRJ141 
(C57BL6J/129P2) mice were rederived from frozen embryos distributed by the UC-
Davis branch of the Mutant Mouse Regional Resource Centers (MMRC). They were 
then back-crossed to C57BL6J mice for at least 10 generations. Mouse tail DNA and 
primers complementary to sequences flanking the gene trap (RRJ141, 
BayGenomics, gene trap vector pGT0Lxf) insertion site were used for genotyping. 
The mice used in the experiments are summarized in Table 4. 
 
Table 4. Experimental animals. 
Mouse Line Genotype Background 
sestrin 2 KO Sesn2-/- C57BL/6J 
WT C57BL/6J C57BL/6J 
4.1.3 Housing 
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All animals were housed under controlled conditions (20-23ºC and 40-70% 
humidity) of an equal daylight/dark cycle of 12 hours. Food (Altromin®Standard Diet 
Food) and water was supplied ad libitum. The animals were randomly allocated to 
the experimental groups of all studies and were kept in polycarbonate type 2 and 3 
cages with woodchip bedding and red shelters. 
4.1.4 Sestrin 2 study/smoke exposure mice groups: 
9-15 (equally distributed male and female) mice to smoke-exposed or 
unexposed (control) groups with parallel groups for: (i) lung function tests (dynamic 
compliance) ii) hemodynamics (right ventricular and systemic arterial blood pressure) 
measurements, iii) alveolar morphometry, (iv) protein and mRNA analysis v) elastin 
quantification by image analysis.  
4.1.5 sestrin 2 study mice groups: elastase-induced emphysema 
8 (3 female, 5 male) mice were assigned to elastase treated or saline treated 
(control) groups with parallel groups for: (i) lung function tests (dynamic compliance 
and resistance measurements), ii) hemodynamic (right ventricular and systemic 
arterial blood pressure) measurements, iii) alveolar morphometry, (iv) protein and 
mRNA analysis.  
4.2 Experimental designs 
4.2.1.Experimental design of tobacco smoke exposure of RRJ141 mice 
Sestrin 2 KO and WT mice were exposed to the primary smoke of the 
standardized 3R4F research cigarettes; (Kentucky, Lexington, KY, USA). The 
smoking machine employed ensured a constant total particulate matter (TPM) 
concentration of 140 mg/m3 of cigarette smoke in a mixture with fresh air in the 
chamber and the mice were exposed for 6 h/day, 5 days/week for up to 8 months. 
Age-matched control mice were kept under identical conditions except for the smoke 
exposure.  
 
Experimental plan / time table of analysis 
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Figure 3. Experimental plan of sestrin 2 mice smoke exposure.  
At the end of the experiment (8 months) the mice were subjected to lung function and hemodynamic 
measurements, heart ratios, alveolar morphometry, mRNA and protein analysis, elastin quantification 
by image analysis. (se: smoke-exposed) 
 
 
 
Figure 4. The smoke generator used in the experiments. 
 
4.2.2 Experimental design of elastase-induced emphysema in RRJ141 mice 
Sestrin 2 KO and WT mice started being treated with imatinib or placebo on 
Day 0. Three days later mice received either PPE (24U/kg of BW in 100μl of saline) 
or 100μl of saline alone. The imatinib/placebo (drinking water) by oral gavage 
treatment continued for six weeks after the elastase instillations. At that timepoint the 
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mice were sacrificed and the investigations were performed according to Fig.5 (time 
plan). The mice were divided into groups according to Fig. 6 (groups). 
 
 
 
D0 D3
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Figure 5. Time schedule of elastase-induced emphysema in sestrin 2 KO and WT mice.  
Six weeks after the elastase instillations, the mice were subjected to lung function and hemodynamic 
measurements, alveolar morphometry, mRNA and protein analysis. 
 
 
 
Figure 6. Mice groups in the elastase-induced emphysema in sestrin 2 mice experiment. 
4.2.3 Elastase intratracheal instillation in mice 
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Elastase 
The elastase used was PPE (ET947, EPC, USA). The activity of the enzyme 
was measured using the assay with Suc-Ala-Ala-Ala-pNA as a substrate, according 
to the following protocol: 
Protocol for elastase activity assay 
DETERMINATION OF PORCINE PANCREATIC ELASTASE ACTIVITY  
Assay with Suc-Ala-Ala-Ala-pNA (EPC No. NS945) as substrate (44). 
Materials Required 
1. Tris buffer; 0.1 M Tris pH 8.3 at 25ºC.  Dissolve 6.75 g Tris-HCl and 8.14 G Tris base in 
900 ml H2O.  Determine pH at 25ºC.  Titrate if necessary to pH 8.3 with 0.1 M HCl or 0.1 M 
NaOH.  Dilute to 1000 ml with H2O. 
2. NaOAc-NaCl buffer; 0.05 M NaOAc pH 5, containing  0.1 M NaCl.  Combine 14.8 ml of 
0.2 M HAc and 35.2 ml of 0.2 M NaOAc and 100 ml 0.2 M NaCl. Bring to 200 ml with H2O.  
Titrate to pH 5 at 25ºC. 
3. Substrate solution; 2.5 mM in 0.1 M Tris pH 8.3.  Utilizing a 25 mg vial of N-Suc-Ala-Ala-
Ala-pNA (EPC No NS945), dissolve the contents with 22 ml of tris buffer.  (Note: Use about 
10 ml of the buffer for 5 flushes of the substrate vial.)  Dissolve with stirring.  Store at 5ºC. 
4. Elastase solution; dissolve 1.0 mg per ml in the NaOAc-NaCl buffer.  Prepare a 
secondary solution of 0.10 mg per ml in the same buffer.  Keep both solutions cold in an ice 
bath. 
Procedure 
1. Adjust the spectrophotometer to 410 nm and cell temperature to 25ºC.  
2. Equilibrate 2.5 ml of Tris buffer and 0.5 ml of substrate solution to 25º in the cell. 
3. Add 0.005 ml of the 0.10 mg ml elastase solution, mix and determine the rate increase in 
absorbency at 1 minute intervals.  The rate increase should be ca. 0.025 – 0.040 ∆410 nm per 
minute. 
Calculation of Specific Activity 
Є, 1%, 280 = 19.5 for porcine pancreas elastase 
mg/ml = A280 x 0.51  
Vol = 1.505 ml      A=410 nm     T=25ºC     Light Path=1.0 cm 
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8.8=mM extinction coefficient of pNA at 410 nm 
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From the Manufacturer, modified for volume used: 
http://www.elastin.com/methods/PPEassayusingNS945assubstrate.aspx  
The prepared stock solution of elastase for the instillation had a concentration 
of 0.6 U/100 μl. 
Anaesthesia and elastase instillation. 
Prior to intubation, the animals were anaesthetized with a mixture of 5% iso-
ﬂurane (Baxter) in O2 in an anaesthetic chamber. The animals were monitored at all 
times. The onset of surgical anaesthesia was controlled by using the loss of the 
pedal reﬂex as an index. Eye cream was applied to the corneas to prevent damage 
from dryness. The animals were placed on the mounting support from which they 
were suspended by their front incisors in a manner so that the neck and trachea were 
straightened. Anaesthesia was maintained by the use of a self-made face mask (1ml 
syringe) with a mixture of 2–3% isoﬂurane in oxygen. To illuminate the larynx and 
make the vocal chords visible one of the ﬁber optic arms of a strong external halogen 
light source (Schott KL200) was positioned very close to the front of the neck of the 
animal while the other fiber optic arm was used to illuminate the oral cavity. The 
intubation was performed under a dissecting microscope. After the displacement of 
the tongue the larynx and vocal chords were clearly visible and the intubation tube 
was inserted in the trachea.  The tube used was an intravenous catheter (Neoflon 
outer sheath, 20G x 11/4”, 33mm length, B. Braun, Germany) that was carefully 
pushed between the vocal chords. 100 μl of the elastase solution followed by 200 μl 
of air for even distribution in the lungs was instilled through the endotracheal tube 
using a 1ml syringe and another intravenous catheter of smaller diameter (Neoﬂon 
outer sheath, 24G gauge, 19 mm length; Becton Dickinson, Sweden) attached to it. 
After the instillation the mice were placed in a cage under an infrared lamp and were 
allowed to recover. 
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4.3 In vivo investigations 
4.3.1 Anaesthesia and mouse preparation 
After the end of each experiment the mice were anticoagulated with heparin (1000 
U/kg, i.p) about 20 minutes before the beginning of the surgical interventions and 
anesthetized with ketamine (60 mg/kg body weight) and xylazine (10 mg/kg body 
weight) intraperitoneally. Their temperature was maintained at a physiological level 
(≈37°C) throughout the experiment. After the evaluation of the depth of anesthesia 
the mice were transferred to a Single-Chamber Plethysmograph for mice (Fig.7), 
placed in the supine position fixed on a rubber pad and subjected to the in vivo 
investigations.  
1) PTM 
2) Inspiration/
expiration  
3) Tracheal
Pressure
4) Tracheal
cannula
5) Arterial
catheter(SAP)
6) RV catheter
(RVSP)
j
k
l
m no
 
meas ptm correstio 
Figure 7. Lung function and hemodynamics body measurement setup. 
PTM: pneumotachometer, SAP: systemic arterial pressure, RVSP: right ventricular systolic pressure. 
4.3.2 Lung function tests 
After the disinfection of the skin using an alcohol-based povidone-iodine solution 
(Braunoderm®), also used to keep the hair away from the surgical field) an incision 
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on the ventral surface of the neck was performed. The removal of the skin 
(approximately 1cm2) and subcutaneous tissue revealed the (left and right) 
submandibular salivary glands. Following the preparation and the removal of theses 
glands on the side, the muscle layer (M. sternohyoideus and M. thyreohyoideus, left 
and right) covering the ventral surface of the trachea was visible. The muscles were 
removed on the side and the trachea was prepared. A surgical thread was guided 
from under the trachea and a loose double-knot was made over it. Following 
tracheostomy (small incision between cartilageous rings), the animals were intubated 
with a tube (Vasofix® Safety Cannula for vein catheter support 20G, cut at the same 
length for all experiments) which was fixed with the thread. The ventilation of the 
lungs began immediately using a mouse ventilator for mice, set to a stroke volume of 
10μl/g of BW, a respiratory rate of 150 breaths/min and a PEEP of 2 cmH2O for the 
prevention of lung derecruitment. The tracheal cannula was connected to a 
pneumotachometer and the pressure difference produced in it was converted by a 
differential pressure transducer (VALIDYNE DP 45-14, Hugo Sachs Electronics, 
March-Hugstetten, Germany) into an electrical signal that is proportional to the 
respiratory flow. The measurement of the dynamic compliance (CL,dyn) was performed 
in the living mouse by using the HSE PULMODYN software (Hugo Sachs 
Electronics, March-Hugstetten, Germany). The duration of the measurement was 
approximately 5 minutes. 
4.3.3 Hemodynamic measurements 
After the completion of the compliance measurements the head of the mouse 
was moved and tilted to the right. The left A. carotis was prepared by passing two 
curved forceps under it and carefully pulling the connective tissue and the N. vagus 
aside. Two surgical sutures (cranial and caudal) were passed under the vessel. A 
square knot was made to the cranial suture and it was then fixed on the upper right 
corner of the water bed using tape with appropriate tension. A simple loose knot was 
made in the caudal suture and the carotid artery was occluded with a microsurgery 
clip the nearest possible to the entrance of the artery in the thoracic cavity. The 
measuring equipment was at this point fixed to a value of 0 mmHg. A small incision 
was made on the artery and an arterial catheter was introduced in the vessel and 
fixed with the caudal suture. The surgical clip was removed and the SAP 
measurement was initiated. 
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The right V. jugularis was prepared in a way similar to that for the left carotis. 
The caudal suture was pulled lightly during the incision of the vessel and the insertion 
of the catheter (PE-10 tube) as a means of occlusion to prevent bleeding through the 
incision. For the same reason after the introduction of the tip of the catheter into the 
vessel the simple knot of the caudal suture was tightened with enough tension to 
stop the bleeding but still permit the unobstructed advance of the catheter through it 
until it reached the right ventricle.  
Both catheters (Fig. 7, points 5 and 6) used for the hemodynamic 
measurements are fluid filled and the pressures are converted into electrical signals 
with the use of transducers and interpreted by the computer software LabTech Pro®. 
The measurement of the RVSP and SAP lasted for approximately 10 minutes. After 
the end of the lung function test and the hemodynamics measurements, the mice 
were euthanized by exsanguination through the heart. 
4.4 Alveolar morphometry 
The abdominal surface of the body was again disinfected with Braunoderm®. 
An incision was made to open the abdomen and extended medially to reveal the 
xiphoid process of the sternum. The thoracic cavity of the mice was opened by 
holding that process up, making a small incision in the diaphragm and cutting on the 
medial line of the body until the jugular notch was reached. After separation of the 
diaphragm from the inferior thoracic aperture using a pair of microsurgery scissors, 
the two sides of the thoracic cage were pulled and fixed aside using needles. 
Elevating and slightly tilting the heart from its apex the A. pulmonalis was displayed 
and isolated with the use of a curved forceps passing behind it and between the 
vessel and the base of the heart. A surgical suture was passed through the same 
point and a square knot was tied loosely over the pulmonary artery. A cannula was 
inserted in the artery through a small incision in the right ventricle and was fixed by 
tightening the knot. Isotonic saline solution was administered through that cannula 
into the lungs to remove the remaining blood that exited through a second small 
incision in the left ventricle kept open with the help of microsurgery scissors. The 
right lung was removed and kept in liquid nitrogen for molecular investigations. The 
tracheal tube was removed and another 20G cannula connected to a 50ml syringe 
through an extension set was inserted in the trachea.  
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The left lung was fixed by infusing 4.5% formaldehyde solution at an inflating 
pressure of 22 cmH2O (Fig. 8). The lungs were removed from the thoracic cavity after 
20 minutes and were immersed in respective fixative solution overnight. The second 
day they were transferred in 0.1M PBS, the third day in 50% ethanol and the fourth in 
70% ethanol. Afterwards the lungs were placed in histological microcassettes and 
dehydrated using an automated dehydration unit (TP 1050, Leica Microsystems, 
Nussloch, Germany) with a program specific for alveolar structure maintenance. 
 
 
 
22cm
 
Figure 8. Lung fixation setup. 
 
The lungs were afterwards embedded in paraffin. The blocks were placed in a 
cooling plate (EG 1150C Leica Microsystems, Nussloch, Germany) and subsequently 
to a cool chamber until the paraffin became solid. The following step was the 
preparation of 3μm thick sections on histological slides at the same level for all lungs 
(entrance of the bronchus in the lung).  
The sections were stained with hematoxylin-eosin staining. The steps followed 
(removal of paraffin with xylene, rehydration of tissue with decreasing strengths of 
alcohol, staining of the nuclei with hematoxylin, blueing of the nuclei for better 
contrast, staining of non-nuclear elements with eosin, dehydration with increasing 
strengths of alcohol, “clearing” with xylene and placement of the coverslip) are given 
in  the protocol described in Table 5. 
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Table 5. Hematoxylin-Eosin staining protocol 
Step 
Duration in 
minutes 
Reagent/Solution Effect 
1 60 Incubation at 60ºC 
Removing of paraffin 
2 10 Xylol 
3 10 Xylol 
4 10 Xylol 
5 5 Absolute ethanol 99,6% 
Hydration of the section 
 
6 5 Absolute ethanol 99,6% 
7 5 Ethanol 96% 
8 5 Ethanol 70% 
9 2 Aqua dest. 
10 20 Mayer’s Hematoxylin solution Staining of nuclei 
11 5 Wash under running tap water Rinsing-“blueing” 
12 1 Ethanol 96% Differentiation 
13 4 Alcoholic Eosin-y solution 
Staining of non-nuclear 
elements 
14 rinse Aqua dest. Rinsing 
15 2 Ethanol 96% 
Dehydration 
16 2 Ethanol 96% 
17 5 Absolute ethanol 99,6% 
18 5 Isopropyl alcohol 99,8% 
19 5 Xylol 
„Clearing“ of tissue 20 5 Xylol 
21 5 Xylol 
22  Mount with Pertex / Corbit Apply the cover slip 
 
The stained sections were evaluated using the Leica Qwin software and the 
macro for alveolar morphometry. As a first step the white balance of the slides was 
set so that the program could later automatically identify the parts of the section 
corresponding to air (white part). The second step was the scanning of the section 
with the 5x objective to produce a mosaic picture of the section and to exclude the 
surrounding space of the lung and the big airways and vessels form the following 
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analysis of the individual fields. A total of 30-100 fields from each lung were analyzed 
with the 10x objective in the third step. The program identified the airspace (white 
color) and the lung structures (septal, airway and vessel walls, red color). Since 
emphysema is defined as “a condition of the lung characterized by abnormal, 
permanent enlargement of the air spaces distal to the terminal bronchiole,” and it 
involves the lung parenchyma, the airway structures proximal to the terminal 
bronchiole and vessels as well as the dead space surrounding the lung were 
excluded from the analysis. Fig.9 shows how the software analyses the photos taken 
with the microscope. Large airways proximal to the terminal bronchiole and vessels 
are excluded (white part), while the parenchymal part taken into account for the 
measurement (yellow part) is analyzed for the measurements performed by the 
program: Airspace%, Septal Wall Thickness and Mean Linear Intercept. The average 
values of all the fields for every lung were calculated and used to calculate the 
average values for each experimental group. 
 
    
Figure 9. Image analysis for alveolar morphometry.  
Yellow color: airspace mask, red: lung structures mask used by the software for image analysis. 
4.5 Immunohistochemistry and immunofluorescence 
  5-μm tissue sections were deparaffinized, rehydrated, and then the antigen 
was retrieved by boiling in citrate buffer, pH 6.0 (Invitrogen), for 20 minutes in a 
microwave, and allowed to cool down for 30 minutes. Following rinsing in distilled 
H2O and PBS for 5 minutes, the inactivation of the endogenous peroxidases was 
ensured by treatment of the slides with H2O2Block (Thermo Scientific) for 10-15 
minutes and with Ultra V Block (Thermo Scientific) for 5 minutes. Steps of rinsing in 
dH2O and soaking in PBS for 5-10 minutes followed, and then blocking nonspecific 
METHODS   
 50 
protein-binding sites was achieved with incubation with 2% BSA in PBS for 1 hour. 
Exposure to the specific antibodies was performed with 2% BSA in PBS at 4°C 
overnight. The excess antibody was removed, the secondary antibody (biotin-
labelled) (KPL) was applied to the slides (30 minutes, room temperature) followed by 
treatment with streptavidin peroxidase (KPL) (30 minutes, room temperature). After 
washing, incubation with AEC Chromogen Single Solution (Thermo Scientific) 
followed (10-20 minutes, room temperature). Counterstaining was done with Mayer’s 
Haematoxylin Solution (Sigma) and finally the coverslips were mounted with Immuno 
Histo Mount (Santa Cruz Biotechnology). For the TTF1 staining, the staining 
procedure followed involved the M.O.M. Kit (Mouse on Mouse Kit, Vector 
Laboratories) according to the manufacturer’s instructions. (Performed by 
collaboration partner: AG von Melchner, University of Frankfurt Medical School). 
4.6 Heart preparation and heart ratio calculation 
Just before the explantation of the lungs, the hearts were removed by cutting 
off the vessels connecting them to the body and removing the adjacent connective 
tissue. The hearts were then dissected under a stereoscope. The atria and vessel 
trunks were removed to the level of the mitral and tricuspid valves. The right ventricle 
was excised and separated from the left ventricle and septum. The two parts of the 
heart (right ventricle and left ventricle plus septum) were dried for at least 3 days at 
room temperature and then weighed separately to obtain the right ventricle to left 
ventricle plus septum ratio (Dumitrascu et al., 2006) according to the following 
equation: 
 
 
septumventricleLeft
ventricleRight


 
 
ratioHeart  
 
Fig. 10 illustrates the heart structures used in the calculation. 
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Figure 10. Schematic illustration of the heart.  
Structures used in the determination of right heart hypertrophy by calculation of the heart ratio (right 
ventricle to left ventricle plus septum). a) transverse plane, dorsal view (after removal of atria and main 
vessels), b) sagittal plane, left lateral view 
4.7 Quantification of lung elastin by image analysis (sestrin 2 mice smoke 
exposure experiment) 
Paraffin sections of 3µm thickness, were analysed using the macro for cell 
counting of the Leica QWin software and the 40x objective. The slides were stained 
with Weigert’s resorcin-fuchsin solution and counterstained with nuclear fast red 
according to the protocol presented in Table 6. Paraffin wax was removed through an 
initial step of heating and then consecutive changes in xylol. The tissue was 
rehydrated with passes in decreasing strengths of alcohol. The tissue was afterwards 
rinsed and rehydrated with increasing strengths of alcohol. The next step was the 
“clearing” the tissue in xylol and finally the coverslips were placed. Depending on the 
size of the lung section, 175-370 images were analysed. 
The number of intact elastin fibres for each image that covered an area of 
0.07598346mm2, was counted (Seimetz et al., 2011). The number of intact fibres per 
area was then calculated according to the following equation:  
 
 



2mm 0,07598346 x images
fibersintact 
  fibersintact  
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Table 6. Weigert’s elastic stain protocol. 
Step Duration  Reagent/Solution Effect 
1 60 Incubation at 60ºC 
Removing of paraffin 
2 10 Xylol 
3 10 Xylol 
4 10 Xylol 
5 5 Absolute ethanol 99,6% 
Hydration 
6 5 Absolute ethanol 99,6% 
7 5 Ethanol 96% 
8 5 Ethanol 70% 
9 1 0 - 2 4  hrs  
Resorcinol fuchsine 
solution acc. to Weighert. 
Staining of elastic 
fibers 
10 2x rinses Distilled Water Rinsing 
11 10 
Nuclear fast red 
aluminium sulphate 
solution 
Counterstaining 
12 2x rinses Distilled Water Rinsing 
13 1 Ethanol 70% 
Dehydration 
14 2 Ethanol 96% 
15 3 Ethanol 96% 
16 5 Isopropyl alcohol 99,8% 
17 5 Isopropyl alcohol 99,8% 
18 5 Xylol 
„Clearing“ of tissue 19 5 Xylol 
20 5 Xylol 
21  Mount with Pertex / Corbit 
Mounting the cover 
slip 
4.8 RT-PCR 
RNA isolation was performed using the TriReagent (Sigma) protocol according to 
the manufacturer’s instructions. Gene expression analysis through Real-time RT-
PCR was performed using SYBR Green (ABgene, Epsom, UK) and/or TaqMan 
chemistry (Life Technologies) in an Opticon 2 qPCR machine (MJ Research). 
Random priming and Superscript II reverse transcriptase (Invitrogen) were used to 
synthesize cDNA from total RNA. cDNA derived from 7.5-15.0 ng of total RNA, 1× 
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ABsolute SYBR fluorescein mix (ABGene), and 5 pmol of gene-specific primers in a 
total volume of 25 μl were used to run PCR reactions as triplicates on 96-well plates. 
For the normalization of the reactions, RT-PCR reactions for RNApolII were carried 
out simultaneously using the primers 5’-ATGAGCTGGAACGGGAATTTGA-3’ and 5’-
ACCACTTTGATGGGATGCAGGT-3’. The temperature profile of the reactions is 
shown in Table 7. 
Table 7. Temperature profile of the PCR reaction. 
Temperature Duration No. of cycles 
94°C 10 min  
94°C 15 seconds 
40 cycles 61°C 30 seconds 
72°C 30 seconds 
 
The primers used for expression analysis are given in Table 8. 
Table 8. Primers used for sestrin 2, PDGFRβ and KGF. 
Gene Forward primer Reverse primer 
sestrin 2 5’-ATA ACA CCA TCG CCA TGC AC-3’ 5’-TTG AGG TTC CGT TCC AGG AG-3’ 
PDGFRβ 5’-CCA CCA TGA AAG TGG CTG TC-3’ 5’-TCC ACC AGA TCA CCG TAT CG-3’ 
KGF 5’-CGA GCG ACA CAC CAG AAG TT-3’ 5’-CAC GGT CCT GAT TTC CAT GA-3’ 
 
4.9 Western blotting 
The detection of the KGF and PDGFRβ proteins from mouse lung fibroblast 
lysates and concentrated conditioned media was performed using Western blotting. 
The cells were lysed with an ice-cold RIPA buffer (cell signaling, # 8906) 
supplemented with PMSF (1mM, final concentration) for 20 minutes and cleared of 
debris by centrifugation (20 minutes, 13000 RPM at 4ºC). The conditioned medium 
was tenfold concentrated by passing through a 3-kDa cut-off filtration 
membrane. Protein concentration was measured by spectrophotometry and equal 
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protein concentration was adjusted by addition of RIPA buffer. Equal amounts of 
protein were separated by polyacrylamide gel electrophoresis (PAGE) (NuPAGE, 4-
12% Bis-Tris precast gels, invitrogen), containing sodium dodecyl sulfate (SDS) for 
protein denaturation. Gels were run with NuPAGE® MOPS SDS Running Buffer 
(invitrogen). The total amount of protein loaded per sample was 10 μg. Protein 
samples were supplemented with NuPAGE® LDS Sample Buffer4x, 1x end 
concentration). 5% of mercaptoethanol was added and the samples were heated to 
95oC for 3 minutes. 5 μl of a marker (Seeblue plus2, invitrogen) were applied as a 
standard. The proteins were then transferred to a nitrocellulose (Biorad) membrane 
using a semi-wet blotting system (XCell II™Blot Module, invitrogen) by 
electrophoresis (35 Volts, 1.5 hrs). 
The membrane was afterwards blocked in TBST/5% dry fat free milk buffer for 
1 hour for non-specific binding saturation. An overnight incubation with the primary 
antibody (dissolved in 5%milk buffer) followed. The following day the membrane was 
washed 3 times and incubated with the secondary antibody for 1 hour. After three 
washing steps the membrane was incubated with a chemiluminescent reagent (ECL: 
mix ECL I and ECL II 1:1 shortly before use) for fluorescent detection of horseradish 
peroxidase (HRP) conjugates. ECL I: Luminol (2.5 mM), cumaric acid (0.4 mM), 
TRIS-HCl pH 8.5 (100 mM), ECL II: H2O2 (0.028%), TRIS-HCl pH 8.5 (100 mM). The 
protein bands were visualized and analyzed using the FluorChem Q Imaging system 
(Alpha Innotech). 
For the reincubation of the membrane with β-actin the membrane was stripped 
with an one hour incubation in stripping buffer (RestoreTM PLUS Western Blot 
Stripping Buffer, Meridian, Rockford USA).  Afterwards, the already described steps 
for washing, blocking and incubation with a primary and seconday antibody were 
followed. 
4.10 Cell cultures and preparation of conditioned media  
Mouse lung fibroblasts (MLFs) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, High Glucose, Sigma) supplemented with 10% fetal calf serum 
(FCS), 2  mM glutamine (Gibco) and 1% penicillin/streptomycin (Gibco). For the 
preparation of MLF conditioned media (CM) 90% confluent cultures were used after 
incubation of the cells in serum-free DMEM for 48 hours. Subsequently, the MLF CM 
was filtered using a 0.2 μm Millipore filter and was used immediately or at a later time 
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point after shock-freezing in liquid nitrogen and storage at −70°C. MLF CMs used in 
western blot analysis were concentrated after passing through a 3-kDa cut-off 
filtration membrane (Vivaspin 20, Sartorius).  
4.11 ROS measurements  
The release of superoxide from MLFs measurement by EPR was performed 
as previously described (Veit et al., 2013). Briefly, EPR measurements were 
performed at −170°C using an EMXmicro Electron Spin Resonance (ESR) 
spectrometer (Bruker, Karlsruhe, Germany) and 1-hydroxy-3-methoxycarbonyl-
2,2,5,5-tetramethylpyrrolidine (CMH, Noxygen) as the spin probe for detection of 
intra- and extracellular superoxide production. To assess the superoxide signal as 
part of the total CMH signal, parallel samples that contained either CMH alone or 
combined with superoxide dismutase (SOD) conjugated to polyethyleneglycol (PEG-
SOD) were measured to avoid issues arising from the reaction of CMH with 
superoxide and peroxynitrite. For this purpose, incubation of duplicate samples of 
2×105 cells were incubated for 2 hours at 37°C with 15 U/ml PEG-SOD (Sigma) and 
afterwards CMH (500  μM) ± PEG-SOD was added. The samples were then 
incubated for another 20 minutes followed by shock-freezing and storage in liquid 
nitrogen. The frozen samples were used for spectrometry using specific conditions 
(g-factor= 2.0063, center field= 3349.95G, microwave power= 200 mW, sweep time= 
20 seconds, sweep number= 5). 
4.12 Statistical analyses 
All data presented are expressed as means ± SEM. Analysis of variance 
(ANOVA) with the Newman-Keuls post-test for the comparison of multiple groups 
was performed using the Prism software. For comparison of two groups the Student’s 
t-test was employed. A P value <0.05 was considered statistically significant for all 
analyses. The significance differences between two groups indicated in the graphs 
as asterisks represent p-values as follows: * p<0.05,** p<0.01,*** p<0.001. 
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5. RESULTS 
Portions of this study were performed in collaboration with the group of 
Professor Harald von Melchner, University of Frankfurt Medical School. Data which 
are important for the concept and interpretation of the present study but were not 
perfromed by myself but by the Frankfurt group are given in addition to the own 
results. If such data are given, it is explicitly stated that these data were provided by 
Prof. Harald v. Melchner. 
5.1 Regulation of sestrin 2 and PDGFRβ mRNA in lungs of mice by smoke 
exposure. 
The first step in the elucidation of the role of sestrin 2 in the development of 
smoke-induced emphysema was the determination of regulation of sestrin 2 and 
PDGFRβ mRNA by smoke. Gene expression analysis from lung homogenates of WT 
and sestrin 2 KO mice after 8 months of smoke exposure, demonstrated that sestrin 
2 mRNA was upregulated in the lungs of mice when compared to respective controls 
(Fig. 11a). In contrast, PDGFRβ mRNA was downregulated in the lungs of the WT 
mice while no such downregulation was observed in the lungs of sestrin 2 KO 
smoke-exposed mice (Fig. 11b). 
a)   b)  
 
Figure 11. Regulation of sestrin 2 and PDGFRβ in cigarette smoke-exposed and control 
mice.   
qRT-PCR analysis of a) sestrin 2, b) PDGFRβ. Sestrin 2 is upregulated and PDGRβ is downregulated 
in the lung of mice after smoke exposure. * p<0.05. Sesn2: sestrin 2 mRNA, PDGRβ: PDGFRβ 
RESULTS     
 57 
mRNA, RA: room air, SE: smoke-exposed, WT: wild type, sestrin 2 KO: sestrin 2 knockout. Data were 
provided by Prof. von Melchner, University of Frankfurt Medical School. 
5.2 Sestrin 2 inactivation protects mice from smoke-induced emphysema. 
5.2.1 Sestrin 2 inactivation protects from a decline in lung function in smoke-
exposed mice. 
To estimate the extent of the effect of smoke exposure on lung function, 
dynamic lung compliance measurements were performed. Results from WT and 
sestrin 2 KO mice revealed that the sestrin 2 inactivation protected the mice from 
developing emphysema that would impair their lung function. While the wild type 
mice exhibited a decline in lung function as indicated by the significant increase in 
dynamic lung compliance, the same effect of smoke was not observed in the lungs of 
the KO mice (Fig. 12). While there were no significant differences between the 
smoke-exposed WT and sestrin 2 KO mice groups, the absence of a significant effect 
of smoke exposure on the sestrin 2 KO mice is clearly demonstrated by the absence 
of a significant change in lung compliance between the two sestrin 2 KO mice groups 
(control and smoke-exposed). 
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Figure 12. Dynamic lung compliance measurement in wild type and sestrin 2 knockout 
mice after smoke exposure.  
Impaired lung function indicated by an increase of dynamic lung compliance in WT mice after 8 
months of smoke exposure. *** p<0.001. WT: wild type, KO: sestrin 2 knockout, se: smoke-exposed 
n= 9-15 mice/group. 
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5.2.2 Sestrin 2 inactivation protects from the development of pulmonary 
emphysema in smoke-exposed mice. 
Lungs of mice from all experimental groups underwent morphometric 
evaluation (alveolar morphometry). Lung tissue destruction and airspace 
enlargement were evaluated by analyzing 3 parameters: a) airspace %, b) septal wall 
thickness (SWT) and c) mean linear intercept (MLI). Smoke exposure resulted in a 
significant increase of airspace % and MLI and a decrease of SWT in the lungs of 
WT mice. No significant changes were observed in the sestrin 2 KO mice. The 
results indicating structural alterations in WT mice but not in KO mice are presented 
in Fig. 13 and representative images of the lungs are given in Fig. 14. 
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Figure 13. Alveolar morphometrical evaluation of lungs of WT and sestrin 2 KO mice after 
8 months of smoke exposure. 
Parameters evaluated: a) airspace %, b) septal wall thickness c) mean linear intercept .* p<0.05, **  
p<0.01,*** p<0.001. WT: wild type, KO: sestrin 2 knockout, se: smoke-exposed, n= 9-15 mice/group.  
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Figure 14. Representative images of lungs of wild type and sestrin 2 knockout mice 
exposed to room air (control) or cigarette smoke (se).  
Alveolar morphometry (H&E staining). Magnifications appearing in the panel from left to right: 10x, 
20x, 40x. WT: wild type, KO: sestrin 2 knockout, se: smoke-exposed. 
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5.2.3 Smoke exposure does not result in the development of pulmonary 
hypertension and right heart hypertrophy in sestrin 2 knockout mice. 
After the end of eight months smoke exposure, the wild type mice developed 
pulmonary hypertension as shown by the significant increase of the right ventricular 
systolic pressure (RVSP) in the smoke-exposed mice when compared to the control 
ones. This is in contrast to the sestrin 2 KO mice where no significant increase of the 
RVSP was observed (Fig. 15a). The knockout mice did not exhibit a significant 
difference between smoke-exposed and control groups. No significant differences 
were observed concerning the systemic arterial pressure (SAP) in all groups (Fig. 
15b). 
The heart ratio calculation demonstrated that while smoke exposure led to the 
development of right heart hypertrophy in the wild type mice, it didn’t have the same 
effect on the KO mice (Fig. 15c). 
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Figure 15. Hemodynamic evaluation in wild type and sestrin 2 knockout mice after 8 
months of smoke exposure. 
Parameters evaluated: a) right ventricular systolic pressure, b) systemic arterial pressure, c) right 
heart hypertrophy  (heart ratios). * p<0.05. WT: wild type, KO: sestrin 2 knockout, se: smoke-exposed 
n= 9-14 mice/group. 
5.2.4 Inactivation of Sestrin preserves the number of intact elastin fibers per 
area in the lungs of smoke-exposed mice. 
After eight months of smoke exposure the number of intact elastic fibers per 
area in the lungs of wild type mice was significantly reduced when compared to their 
respective controls and both the groups of knockout mice. In the knockout mice, 
smoke exposure had no effect and the average number of intact elastic fibers per 
area remained at the same level in the control and smoke-exposed groups (Fig. 16 
and 17).  
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Figure 16. Number of intact elastic fibers per area in lungs of wild type and sestrin 2 
knockout mice after smoke exposure and their respective controls.  
Results of manual counting of intact elastic fibers after staining. * p<0.05. WT: wild type, KO: sestrin 2 
knockout, se: smoke-exposed n= 5. 
     
Smoke-exposed WT 
     
Smoke-exposed KO 
Figure 17. Representative images of lungs of WT and sestrin 2 KO lungs, of mice exposed 
to cigarette smoke (smoke-exposed).  
Arrows mark intact elastic fibers. Scale bars: 100 μm. WT: wild type, KO: sestrin 2 knockout, n= 5. 
5.3 Results of the investigations of the role of PDGFRβ in elastase-induced 
emphysema in sestrin 2 knockout mice. 
To elucidate furthermore the importance of PDGFRβ in the regulation of lung 
maintenance, the elastase-induced emphysema model was employed in combination 
with imatinib (a PDGFRβ inhibitor), or placebo. 
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5.3.1 Inhibition of PDGFRβ accentuates the decline in lung function of sestrin 2 
knockout mice treated with elastase. 
The instillation of elastase caused similar changes in the lung functional 
measurements in both wild type and sestrin 2 knockout mice. Mice treated with 
elastase exhibited significantly higher values of dynamic lung compliance compared 
to their respective controls, 6 weeks after elastase instillation. Sestrin 2 knockout 
mice treated with elastase and imatinib had a significantly higher compliance 
compared to the elastase-placebo treated group. Such an effect was not observed in 
the wild type mice, where treatment with imatinib did not have an effect on lung 
function (Fig. 18). 
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Figure 18. Lung function in WT and sestrin 2 KO mice after elastase treatment ± imatinib.  
* p<0.05,. WT: wild type, KO: sestrin 2 knockout, se: smoke-exposed, n= 5-7. 
One way ANOVA was used to prove the hypothesis that imatinib treatment affected lung compliance 
only in knockout mice. Additional p-values are given to support the expected, negligible effect of the 
treatment in the WT mice. 
5.3.2 Inhibition of PDGFRβ worsens the emphysema of sestrin 2 knockout mice 
treated with elastase. 
Consistent with the results obtained from the lung function measurements, 
elastase application resulted in an increase of the airspace %, septal wall thickness 
and mean linear intercept. Inhibition of PDGFRβ further increased the elastase 
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lesions in the knockout but not in the wild type mice with regards to airspace % and 
mean linear intercept but not to septal wall thickness. 
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Figure 19. Morphometric evaluation of the effect of PDGFRβ inhibition on the elastase-
induced emphysema induction in WT and sestrin 2 KO mice.   
PDGFRβ inhibition further increased the differences in the evaluated parameters in the KO lungs while 
no effect was observed in the WTs. Parameters evaluated: a) Airspace %, b) septal wall thickness c) 
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mean linear intercept.* p<0.05, ** p<0.01,*** p<0.001. WT: wild type, KO: sestrin 2 knockout, se: 
smoke-exposed, n= 5-7. One way ANOVA was used to prove the hypothesis that imatinib treatment 
affected Airspace%, septal wall thickness and mean linear intercept only in knockout mice. Additional 
p-values are given to support the expected, negligible effect of the treatment in the WT mice. 
 
 
Representative images from lungs of all groups in this study are presented in Fig. 20. 
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Figure 20. Representative images of lungs from WT and sestrin 2 KO mice after elastase or 
saline application combined with imatinib or placebo treatment.  
 Pages 66-67. HE staining. Magnifications presented for each lung (from left to right): 5x, 10x. WT: 
wild type, KO: sestrin 2 knockout. 
 
5.3.3 Effect of the inhibition of PDGFRβ in hemodynamics of elastase-induced 
emphysema in wild type and sestrin 2 knockout mice. 
The effect of imatinib on RVSP in the sestrin 2 knockout mice treated with 
elastase produced significantly higher values when compared to their respective 
controls and the mice treated with elastase alone (Fig. 21a). While in the wild type 
imatinib tended to lower the blood pressure (the difference however, was not 
significant) in the WT mice, RVSP was significantly increased compared to the 
placebo-treated group in the sestrin 2 KO mice. The absence of significant changes 
in the SAP between all groups is shown in Fig. 21b. 
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Figure 21. Effect of imatinib in the hemodynamics of wild type and sestrin 2 knockout mice 
treated with elastase.  
Parameters evaluated: a) right ventricular systolic pressure, b) systemic arterial pressure.* p<0.05, ** 
p<0.01 WT: wild type, KO: sestrin 2 knockout. n=5-7. One way ANOVA was used to prove the 
hypothesis that imatinib treatment affected right ventricular systolic pressure and systemic arterial 
pressure only in knockout mice. Additional p-values are given to support the expected, negligible 
effect of the treatment in the WT mice. 
5.4 Sestrin2 inactivation leads to increased proliferation and decreased 
apoptosis in alveolar wall ATII cells. 
The quantification of ATII cells in the lungs of control and smoke-exposed, WT 
and sestrin 2 KO mice revealed that cigarette smoke caused a significantly increased 
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number of  ATII cells in the lungs of KO mice after 8 months of smoke exposure, 
when compared to the lungs of WT smoke-exposed mice (Fig. 22).  
a)  
     
b) 
Figure 22. Staining and quantification of ATII cells in lungs of WT and sestrin 2 KO control 
and smoke-exposed mice.  
a) Quantification of ATII cells in lungs of WT and sestrin 2 KO control and smoke-exposed mice. b) 
Representative images from immunostaining used for the quantification. Black arrows indicate TTF1 
positive cells. Scale bars: 50μm. RA: Room air (control), SE: Smoke-exposed.* p<0.05. Data were 
provided by Prof. von Melchner, University of Frankfurt Medical School. 
 
In contrast, the number of apoptotic cells in the lungs of smoke-exposed 
sestrin 2 KO mice was found reduced when compared to the respective WT groups. 
The frequency of apoptotic cells was obtained by counting 400±50 cells from 6 
randomly chosen fields (Fig. 23 and 24). 
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Figure 23. Quantification of apoptotic (CC3 positive) cells in the lungs of WT and KO smoke-
exposed mice.  
SE: Smoke-Exposed, KO: sestrin 2 knockout.  Results are represented as means ± s.e.m. of n=3 
mice/group.* p<0.05. Data provided by Prof. von Melchner, University of Frankfurt Medical School. 
 
 
       
 
Figure 24. Lung sections stained with anti-cleaved caspase-3 (CC3-Cy3) for 
immunofluorescence confocal microscopy.  
Red stain marks the apoptotic cells and nuclei are stained with blue (DAPI). Scale bars: 50μm. Data 
provided by Prof. von Melchner, University of Frankfurt Medical School. 
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5.5 PDGFRβ signaling contributes to lung maintenance through the induction 
of KGF. 
KGF has long been identified as a stimulator of ATII cell proliferation (Ware 
and Matthay, 2002) and PDGF-BB as its inducer  (Chedid et al., 1994). Thus, KGF 
regulation was investigated in sestrin 2 KO-MLFs. Fig. 25a shows an over 10-fold 
upregulation of KGF mRNA in the fibroblasts. Since the fibroblasts release KGF into 
the culture medium, a comparison of the cytokine levels in conditioned medium (CM) 
from KO-MLFs and WT-MLFs showed significantly higher levels in the KOs. When 
PDGF-BB was added, KGF expression was even more induced, suggesting that 
PDGF-BB is an upstream regulator of KGF expression (Fig. 25b).  
 
    a) b)  
 
Figure 25. KGF expression in WT and sestrin 2 KO-MLFs.  
a) mRNA expression in MLFs, b) western blot of 10-fold concentrated CM. * p<0.05 Data provided by 
Prof. von Melchner, University of Frankfurt Medical School. The multiple bands detected for KGF 
represent differently glysosylated forms of the factor  (Maas-Szabowski et al., 1999). Main band size: 
19 kDa. 
 
5.5 Superoxide anions are required for the induction of PDGRβ signaling. 
Since ROS accumulation has been demonstrated in sestrin 2 KO-MLFs  
(Budanov et al., 2002; Wempe et al., 2010) the next step in the investigations was to 
determine whether there is a ROS dependent mechanism involved in the activation 
of PDGFRβ. Electron paramagnetic resonance spectroscopy showed that levels of 
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O2
– were 4 times higher in KO-MLFs when compared to the WTs (Fig. 26a). When 
WT-MLFs were exposed to phorbol 12-myristate 13-acetate (PMA), a stimulator of 
NADPH oxidase O2
– production, PDGFRβ expression was upregulated. The addition 
of tempol, a superoxide dismutase mimetic led to downregulation, identifying O2
– as 
the responsible ROS subspecies for the induction of PDGFRβ (Fig. 26b and 26c). 
 
a)  
 
b)    C)  
 
Figure 26. Induction of PDGFRβ by O2– in WT- and KO-MLFs.  
a) EPR measurements of O2
–
 levels in KO-MLFs of six independent measurements. AU, arbitrary 
units. b) Representative Western blot of PDGFRβ expression in WT-MLFs after exposure to PMA ± 
tempol. c) PDGFRβ levels quantified by densitometry of three separate experiments. *p<0.05. The 
second band detected for the PDGFRβ represents a partially glysosylated, immature form of the 
receptor which is approximately 170 kDa compared to the fully glycosylated, mature form of 180 kDa 
in size (upper band) (Hart et al., 1987). 
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6. Discussion 
6.1 The mouse model of smoke-induced emphysema 
Cigarette smoke is the main cause of COPD, a pathological condition that is 
the fourth ranking cause of death worldwide (Miniño, 2010). While 95% of cases can 
be attributed to smoking only a small percentage of smokers is susceptible to the 
development of the disease (Fletcher and Peto, 1977). Not only smoke affects 
smokers who are directly exposed to a cigarette’s mainstream smoke but also 
causes problems to non-smokers by second-hand smoke exposure as was recently 
pointed out  (Leberl et al., 2013), being responsible for 1% of deaths worldwide. 
Thus, the smoke-induced emphysema model has been favorably used to mimic the 
disease in several animal species, with rodents being the most commonly used. A 
number of studies has used mainstream smoke as the irritant at a TPM concentration 
comparable to that of 140mg/m3 (Eppert et al., 2013; Leberl et al., 2013; Miller et al., 
2010; Motz et al., 2010a; Motz et al., 2010b; Rangasamy et al., 2004; Seimetz et al., 
2011; Witschi et al., 1997; Woodruff et al., 2009; Yao et al., 2010) as was the case 
with the present study.  
The present study also used the standardized Kentucky 3R4F cigarettes, 
allowing a respective comparison of the own results with other published studies 
using the same reference cigarettes. As the 3R4F has equivalent and comparable 
smoke chemistry and toxicity to its predecessor, the 2R4F (Roemer and Schramke, 
2012), the number of studies that the own results can be compared to, is even 
higher. It is also noteworthy that these cigarettes were designed to represent typical 
products of the tobacco market.  
Additionally, the majority of studies that used comparable smoke 
concentrations and exposure duration employed the same mouse strain, the 
C57BL/6J (Eppert et al., 2013; Miller et al., 2010; Motz et al., 2010b; Seimetz et al., 
2011; Woodruff et al., 2009; Yao et al., 2010). Diversity in the level of susceptibility, 
lung structure, lung function and pathophysiological mechanistic responses to smoke 
has been observed between species and between strains of the same species. 
Guinea pigs have proven to be very susceptible but the number of commercially 
available antibodies to perform molecular investigations is limited; rats have 
demonstrated a resistance to developing emphysema after smoke exposure 
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developing minimal disease and at high concentrations of smoke causes particle 
overload effects (Stevenson et al., 2007), while mice are in the middle with different 
strains exhibiting different levels of susceptibility. In particular, the C57BL6 strain also 
used in this study is the strain used in a large number of studies (Eppert et al., 2013; 
Miller et al., 2010; Motz et al., 2010b; Seimetz et al., 2011; Woodruff et al., 2009; Yao 
et al., 2010) since its deficiency in antielastase  (decreased serum concentration of 
a1-protease inhibitor for elastase (Cavarra et al., 2001; Gardi et al., 1994), high 
contents of elastase and cathepsin G in lysosomes (Gardi et al., 1994) make it mildly 
susceptible and thus popular in similar experimental designs. The chronic smoke 
exposure of a duration of eight months in the own study can be compared to the 
manifestation of pathological changes seen in humans developing COPD after a long 
history of smoking, notably emphysema and pulmonary hypertension (Churg and 
Wright, 2009; Leberl et al., 2013; Seimetz et al., 2011; Wright and Churg, 2008).  
While it has already been demonstrated by previous studies of our research 
group  (Seimetz et al., 2011; Weissmann et al., 2014) that cigarette smoke exposure  
induces similar functional and structural alterations in mice there are some limitations 
and considerations to be taken into account when extrapolating the results to the 
human disease. In this regard, mice do not exhibit the symptoms of the disease that 
humans exhibit and upon which the diagnose of COPD is based like chronic cough, 
phlegm and persistent shortness of breath (Fehrenbach, 2002). Moreover, in our 
smoke-induced emphysema, only cigarette smoke was used as a contributing factor, 
while the pathogenesis of the human disease is multifactorial (Fehrenbach, 2002). 
Another limitation of our model is that it does not result in the airway obstruction seen 
in humans, but more subtle alterations (March et al., 2006). Nevertheless, the aim of 
the own study was the investigation of sestrin 2 in alveolar maintenance, so the 
choice of this model was appropriate. Additionally, the smoke exposure used in this 
study resulted in a mild form of emphysema  in the wild type mice comparable to a 
GOLD stage I/II COPD, rather than the stage III/IV that is normally diagnosed in 
human patients (Churg and Wright, 2009; Wright et al., 2008). However, it does offer 
an insight to pathophysiological mechanisms involved and thus potential early 
interventions that might prove to be useful and easier to design (Churg et al., 2008; 
Churg et al., 2011; Nikota and Stämpfli, 2012). In addition, the alterations observed in 
mice after 8 months of smoke exposure and human patients with developed COPD 
and a history of smoking are similar (Seimetz et al., 2011). Also, with regard to the 
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temporal onset of emphysema development, a chronic exposure to cigarette smoke 
should be used to relate to the human disease, which also manifests after a long-
term exposure (Leberl et al., 2013). 
 
6.2 Structural and functional changes in wild type mice after smoke exposure 
After eight months of smoke exposure the wild type mice displayed a 
significant increase in dynamic lung compliance. The impairment of lung function 
mirrors the structural alterations. A correlation between the degree of 
histopathological changes and lung function has already been demonstrated  (Hogg, 
2008; Nakano et al., 2000). Histopathologically the lungs of the WT mice exhibited an 
increased airspace and thinner alveolar walls (increased airspace & and reduced 
SWT) from the loss of tissue and enlarged alveoli from the rupture of neighboring 
walls (increased MLI). The parameters used for the structural evaluation of the lungs 
used in this study have also been used in other similar investigations (Bracke et al., 
2006; Canning and Wright, 2008; Maeno et al., 2007; Seimetz et al., 2011). The 
damage of elastic fibers in the parenchyma resulted in a loss of elasticity of the 
airway walls that also manifested functionally as an increase in compliance. This 
alveolar wall destruction could be attributed to increased apoptosis after smoke 
exposure and its interaction with inflammation, protease/antiprotease balance and 
oxidative stress. Apoptosis and proliferation of alveolar cells are increased in 
emphysematous lung tissue (Imai et al., 2005). These cell types  (alveolar epithelial 
type I and II, endothelial and myofibroblasts) are in close proximity and have 
significant contacts amongst them (Sirianni et al., 2003). Consequently, severe 
damage to one of them could cause a disruption of the other and furthermore the 
matrix and interstitium. A concordant destruction of these cells is required for the 
disruption of the alveolar wall. 
Cigarette smoke causes lung inflammation characterized by an influx of 
inflammatory cells, notably macrophages, neutrophils and lymphocytes, 
predominantly CD8+ T-lymphocytes. Neutrophils release elastase, reactive oxygen 
species and cytokines that can result in the structural changes characterizing 
emphysema (Chung and Adcock, 2008). It has already been reported by Wang and 
colleagues in a transgenic mouse model that CD8+ cells via expression of IFN-γ 
cause epithelial cell DNA damage and apoptosis correlated to activation of death 
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receptor and mitochondrial apoptosis pathway that finally lead to alveolar 
enlargement and increased compliance (Wang et al., 2000). In their model, cathepsin 
S was instrumental in the IFN-γ induced DNA damage, apoptosis, emphysema and 
protease accumulation (Zheng et al., 2005). Additionally there is a correlation 
between the number of lymphocytes and tissue destruction, and CD8+ cells 
produced type and cytokines, that link CD8+ cells and IFN-γ overexpression to 
emphysema, increased compliance and increased accumulation of inflammatory 
cells. The resulting tissue, lung matrix and elastin degradation would lead to the 
modification of the parameters quantifying (functionally and morphometrically) the 
emphysema seen in the lungs of the WT mice after smoke exposure. Sestrin 2 by 
repressing PDGRβ (and consequently KGF induction) and mTOR signaling could 
contribute to this process by inducing apoptotic and pro-inflammatory effects, 
respectively. 
Cigarette-smoke exposure also results in shifting the protease-antiprotease 
balance towards the side of proteolysis by increasing neutrophil elastase, cathepsins, 
matrix metalloproteinases and decreasing α1-antitrypsin airway epithelium-derived 
secretory leukoprotease inhibitor and tissue inhibitors of matrix metalloproteinases. 
This shift will eventually lead to the breakdown of connective tissue components, for 
the most part elastin. The same fragments of elastic fibers produced also act as a 
chemotactic for monocytes leading to macrophage accumulation and further tissue 
breakdown. Macrophages will produce matrix metalloproteinases  (MMP-2, MMP-9, 
MMP-12), cathepsins (K, L, S) and neutrophil elastase (Petruzzelli et al., 1997; 
Punturieri et al., 2000). This activity of the macrophages of COPD patients is greater 
at a baseline level when compared to healthy smokers and is even more amplified by 
smoke exposure (Lim et al., 2000; Russell et al., 2002a; Russell et al., 2002b). 
Macrophage numbers are also increased by a 25 fold factor in lung tissues from 
COPD patients compared to normal smokers (Retamales et al., 2001) where they 
localize to sites of alveolar wall destruction (Finkelstein et al., 1995; Meshi et al., 
2002).The lung matrix destruction ensuing from the interaction between neutrophils 
and macrophages and the proteolytic enzymes they produce (Maeno et al., 2007), 
promotes airspace enlargement quantified in histological sections as an increase in 
airspace percentage and mean linear intercept (mean distance between alveolar 
walls) and a decrease of septal wall thickness, changes observed in a significant 
degree in the lungs of the WT mice used in the present study.  
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Another contributing factor to the thinning the alveolar wall is the cigarette-
induced apoptosis of ATII cells, an event demonstrated and quantified in the present 
study. Apoptosis has been shown to be increased in emphysematous lung tissue. 
Imai and colleagues showed increased expression of pro-apoptotic proteins like Bax 
and Bad and activation of caspase-3, while the counteracting Bcl-2 could not be 
detected in neither healthy nor damaged lungs (Imai et al., 2005). Kasahara and 
colleagues also showed increased apoptosis of epithelial and endothelial cells in 
lungs with emphysema when compared to healthy lungs from smokers and 
nonsmokers, while they couldn’t demonstrate a difference in apoptosis between the 
lungs of healthy smokers and smokers without emphysema (Kasahara et al., 2000). 
Hodge et al. also reported an increased apoptosis in lungs of smokers even after 
smoking cessation (Hodge et al., 2005). The fact that apoptosis persists after 
smoking cessation (Hodge et al., 2005) further suggests that smoke is not necessary 
for the induction of apoptosis after COPD establishment but that it is the interaction 
between the rest of the pathophysiological mechanisms that regulates this process. 
This interaction between the two most prominent mechanisms of alveolar destruction 
(protease/ anti-protease imbalance and apoptosis) has already been demonstrated 
by studies showing that apoptosis signals are substrates of proteases as in the case 
of the FAS ligand and MMP7 in prostate involution  (Powell et al.). Neutrophil 
elastase causes the impaired clearance of apoptotic cells in cystic fibrosis and 
bronchiectasis by cleaving the phospatidylserine receptor in macrophages. In 
addition, the production of ceramide stimulated by cigarette smoke, also mediates 
apoptosis, proteolysis and alveolar destruction. Additionally, the antiprotease  α1-
antitrypsin has been reported to inhibit staurosporine-induced caspase 3 activation 
(Petrache et al., 2006) providing further evidence for the interaction between 
apoptosis and the protease/antiprotease balance. The loss of tissue and the resulting 
thinning of the alveolar walls render them susceptible to rupturing from the 
application of mechanical forces during respiration which could also contribute to the 
impaired lung function of the smoke-exposed mice.  
Since the alveolar septal walls include vessels and lung maintenance requires 
all of its components to be intact, the vascular compartment might also contribute. 
Liebow demonstrated thin and almost avascular septal walls in emphysematous 
lungs. He further hypothesized that the disruption of alveolar walls could be induced 
by the reduced blood flow (Liebow, 1959). G.W. Wright suggested a “vasculonecrotic 
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nature” of emphysema injury (Wright and Kleinerman, 1963). Such a contribution has 
also been supported by studies demonstrating the involvement of VEGFR blockade 
in the development of emphysema (Kasahara et al., 2000; Morissette et al., 2009; 
Tang et al., 2004). Other studies have demonstrated the connection between VEGF 
and mTOR and the importance of mTOR in emphysema development mainly through 
its inactivation by Rtp801 (Seimetz et al., 2011; Yoshida et al., 2010). 
The upregulation of sestrin 2 in the lungs of the WT mice by smoke could 
theoretically contribute to the development of emphysema through the repression of 
PDFGRβ and mTOR (Wempe et al., 2010) that in turn results in amplification of 
mechanisms (endothelial and alveolar epithelial cell apoptosis, inflammation and 
protease/anti-protease imbalance) that lead to the disruption of lung maintenance 
programs (Fig. 27). 
 
Figure 27. Possible participation of sestrin 2 in the pathogenesis of emphysema through the 
disruption of lung maintenance.  
The repression of PDGFRβ and mTOR signaling leads to the shifting of injury/repair mechanisms 
towards the latter, leading to the development of pulmonary emphysema. 
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6.3 sestrin 2 knockout mice did not exhibit the same functional and structural 
changes as wild type mice after smoke exposure. 
After 8 months of smoke exposure, sestrin 2 KO mice exhibited normal lung 
function and physiological lung structure (alveolar morphometry and intact elastin 
fiber content) and activation of lung maintenance programs (KGF upregulation, ATII 
cell proliferation, elastin production). The basic structure of the lung’s primary 
anatomical and functional unit, the alveolus, is the alveolar interstitium. This structure 
acts as the scaffold on which the cellular components of the alveolar wall proliferate 
and differentiate. Elastin together with collagen are the two prominent components of 
the extracellular matrix network and the thin basement membrane  (80–90 nm width) 
to which the airway epithelial cells are attached (Roche et al., 1989). Being primarily 
composed of elastin, collagen and proteoglycans it is also accountable for the lung’s 
basic mechanistic feature: elasticity. Additionally to the collagen that provides tensile 
strength and elastin being responsible for the distensibility of the lungs, ATII cells 
also contribute to the elastic recoil through the production of surfactant and its effects 
on surface tension. The destruction of elastin, the cleavage of alveolar walls, the 
disturbances in surface tension can lead to both an impaired lung function and a 
respective histopathological appearance of the lungs. The preservation of intact 
elastin fibers, the decreased apoptosis and increased proliferation of ATII cells 
contributes to the prevention of emphysema development in the lungs of the sestrin 2 
KO mice. 
The cells primarily in charge of the production and maintenance of the alveolar 
interstitium are the lung fibroblasts. After any type of injury the repair of lung 
parenchyma relies with the interactions of epithelial cells, mesenchymal cells as well 
as endothelial cells and particularly between fibroblasts and ATII cells who are the 
most active participants in lung maintenance in the adult lung. Our study has 
provided evidence that the inactivation of sestrin 2 in the sestrin 2 KO lungs resulted, 
through the upregulation of PDGFRβ signaling, in the initiation of lung maintenance 
programs. One of the major requirements for alveolar regeneration is the formation of 
the structural scaffold made up by elastin, which then drives alveogenesis (Wendel et 
al., 2000). This process is then completed with the repopulation of the walls by all the 
cellular components that comprise it, an event promoted by pathways induced by the 
inactivation of sestrin 2: PDGFRβ, KGF, (present study) TGF-β and mTOR (Wempe 
et al., 2010). The mechanism of protection of the sestrin 2 knockout mice from 
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developing emphysema can be attributed to the induction of proliferation and 
counteraction of ATII cell apoptosis resulting from the inactivation of sestrin 2. This 
inactivation can lead to enhanced PDGFRβ signaling which in turn stimulates the 
production of KGF by the pulmonary fibroblasts. KGF is a potent mitogen for a 
number of epithelial cells including ATII cells in the lung that mediates their 
maturation and proliferation (Deterding et al., 1996; Schmeckebier et al., 2013). 
While the growth factor is produced by fibroblasts, its receptors are expressed only in 
epithelial cells revealing a paracrine function and an important role in mesothelial-
epithelial interactions (Danilenko, 1999).  
After the disruption of the alveolar epithelial lining by cigarette smoke, the 
restoration process involves the proliferation of ATII cells and their differentiation into 
ATI cells  (Bachofen and Weibel, 1974; Haschek and Witschi, 1979; Rannels and 
Rannels, 1989). KGF has been demonstrated to be an important endogenous trigger 
of alveolar repair in different lung injury models. Charafeddine et al. showed that 
increased expression of KGF in rabbit lungs after hyperoxic injury resulted in an 
increased ATII cell proliferation (Charafeddine et al., 1999) and Ray et al. achieved 
protection by inducibly expressing KGF in  mouse lungs using the same type of 
injury. Additionally, the peak of KGF levels in BALF coincided with the peak of ATII 
cell proliferation after bleomycin injury in rats (Adamson and Bakowska, 1999). In 
another study, administration of exogenous KGF was correlated to declined levels of 
p53, Bax, and Bcl-x proteins that trigger cell death as well as plasminogen activator 
inhibitor-1 after oxygen-induced lung injury in mice (Barazzone et al., 1999).  
The effect of KGF is also mediated by TGF-β. Yildirim et al. showed, using a 
TGF-β1 neutralizing antibody, that recombinant KGF induced elastin expression 
mediated by TGF-β1 in a mouse model of emphysema (Yildirim et al., 2010). TGF-β 
has also been shown to activate elastin transcription in human lung fibroblasts that is 
dependent on phosphatidylinositol 3-kinase/Akt activity (Kuang et al., 2007). The 
repair of the elastic fibers is complex for the elastin producing cells because the 
process of damaged fiber replacement requires a sophisticated coordination of all the 
molecules that constitute the microfibrils as well as the elastin cross-linking enzymes 
also shown to be inhibited by cigarette smoke in vitro (Laurent et al., 1983). This 
inability of the cells in the adult damaged lungs might also be a failure of gene 
reactivation in the required ratios and order necessary for the assembly of the 
complex elastic fiber, a mechanism that appears to work flawlessly in lung 
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development  (Shifren and Mecham, 2006). In the sestrin 2 KO mice, the 
upregulation of KGF also enhanced by the amplified PDGFRβ signaling, could then 
have led to the protection from the disease phenotype. 
As mentioned before, the fragments produced during the breakdown of elastin 
seen in emphysema act as chemotactic factors for monocytes and macrophages in 
vitro  (Hunninghake et al., 1981; Senior et al., 1980; Senior et al., 1984) and have 
been shown to promote the progression of smoke-induced and elastase-induced 
emphysema in mice (Houghton et al., 2006). While the wild type mice in our study 
exhibited a significantly reduced number of intact elastic fibers and consequently an 
increase in the numbers of fragments, the lungs of sestrin 2 knockout mice showed 
practically no difference before and after cigarette smoke exposure, indicating that 
one of the promoting and perpetuating mechanisms that sustain the pathogenesis of 
and development of emphysema was disrupted. Additionally, the induction of 
PDGFRβ expression and the amplification of its signaling in the lungs of the sestrin 2 
knockout mice played a key role in the remodeling and injury repair via the induction 
of KGF and elastin expression.   
Chen et al. detected activated autophagic proteins and increased autophagy 
in the lungs of COPD patients with emphysema. Sestrin 2 has been reported in 
previous studies to be a negative regulator of mTOR through AMPK phosphorylation 
and thus suppress cell growth and proliferation in cancer cells (Budanov and Karin, 
2008; Sanli et al., 2012). While under low hydrogen peroxide concentrations it can 
act as an antioxidant through regenerating peroxiredoxins and maintaining cell 
viability through the Nrf2/ARE pathway, under elevated concentrations of hydrogen 
peroxide it induces apoptosis through the p53 pathway (Budanov et al., 2002; 
Budanov et al., 2010; Sablina et al., 2005; Shin et al., 2012). Recently the role of 
sestrin 2 in induction of apoptosis and the activation of the AMPK/p38/BAX signaling 
pathway in colorectal cancer was investigated and it was demonstrated that 
quercetin-induced apoptosis requires the expression of sestrin 2 as does the 
inhibition of mTOR through AMPK phosphorylation (Kim et al., 2014). In this sense 
the induction of mTOR in the sestrin 2 KO mice also contributes to the restoration of 
the alveolar wall. 
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6.4 Cigarette smoke exposure caused pulmonary hypertension and right heart 
hypertrophy in WT but not in the sestrin 2 KO mice. 
Cigarette smoke resulted in hemodynamic alterations (significant increase of 
RVSP and significant right heart hypertrophy) in the WT mice after 8 months of 
exposure. Smoke exposure leads to vascular remodeling and loss of vessels 
(Seimetz et al., 2011). In the mild form of emphysema produced in the cigarette 
smoke model hypoxic vasoconstriction is most likely not involved in the development 
of the hemodynamic alterations since these mice have been shown neither to be 
exposed to hypoxia nor to suffer from hypoxemia (Seimetz et al., 2011). Such 
mechanisms and chronic hypoxia can, however, be a driving factor of vascular 
remodeling in severe, end-stage COPD (Voelkel et al., 2011).  The vascular 
remodeling induced by cigarette smoke in mice is mainly restricted to the wall media 
with an increased degree of muscularization. However, the vascular remodeling seen 
in COPD involves all layers of the vessel wall with intimal alterations being the most 
prominent, and is not exclusively attributed to prolonged hypoxic vasoconstriction 
(Elwing and Panos, 2008). Inflammatory cells also participate in this process. An 
increase of predominantly CD8+ activated T lymphocytes infiltration in the adventitia 
of pulmonary arteries causes an impairment of endothelium-dependent vascular 
relaxation and intimal thickening (Peinado et al., 2008). The loss of expression of 
enzymes and proteins that are physiologically expressed in the endothelium such as 
prostacyclin synthase, NO synthase and VEGF and VEGFR can lead to EC 
dysfunction, EC apoptosis and intimal fibrosis (Voelkel et al., 2011). In patients with 
mild-to-moderate COPD endothelial dysfunction resulting from this imbalance 
between these vasodilating mediators and vasoconstrictors such as ET-1 and 
angiotensin (Peinado et al., 2008) also triggers hemodynamic alterations. In 
summary, the significant elevation in RVSP seen in the WT mice after 8 months of 
smoke exposure is most probably related to vascular remodeling, inflammation and a 
loss of vessels as previously shown (Seimetz et al., 2011). The increase in RVSP as 
seen in WT mice was not observed in the sestrin 2 KO mice. This protection may be 
attributed to the enhanced mTOR signaling in the KO lungs (Wempe et al., 2010). 
mTOR has been shown to have anti-inflammatory and angiogenic effects. It inhibits 
the production of inflammatory cytokines as IL-12, IL-23, TNF-α and IL-6 through the 
transcription factor NF-κB and simultaneously induces  the release of the anti-
inflammatory IL-10 through STAT3 (Weichhart et al., 2008). It also promotes 
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angiogenesis through inhibiting IL-12 and inducing the expression of angiogenic 
factors such as VEGF, PGDFβ and TGF-α (Advani, 2010). Thus, the activation of 
mTOR signaling in the KO lungs might counteract the effects of smoke in the 
vasculature by counteracting inflammation and rebuilding the lost vessels. 
Additionally, PDGFRβ can contribute to the maturation and stability of these new 
vessels by pericyte recruitment and smooth muscle cell proliferation (Betsholtz, 
2004). The effect of sestrin 2 inactivation on the vasculature in this study is currently 
under investigation. 
6.5 Sestrin 2 is a repressor of PDGFRβ signaling and alveolar maintenance 
programs. 
The present study indicated that the inactivation of sestrin 2 induced PDGFRβ 
signaling and that PDGFRβ can be a key switch in lung injury repair. Additional 
evidence for this conclusion was provided by the exacerbation of lesions in the 
sestrin 2 knockout lungs that underwent an elastase application, after the inhibition of 
PDGFRβ by imatinib. It can be suggested that imatinib abolished PDGFRβ 
participation in the injury repair process which necessitates ECM proteins, 
proliferation of fibroblasts and smooth muscle cells and new vessel formation.  This 
could explain why emphysema was exacerbated in these mice, as indicated by the 
worsening of lung function (increased compliance) and structural lesions in their 
lungs (alveolar morphometry). The absence of a significant effect on lung structure 
and function in the WT mice, where PDGFRβ signaling is steady might be attributed 
to a lower susceptibility to imatinib (Hägerstrand et al., 2006). 
The upregulation of sestrin 2 in the lungs of smoke-exposed WT mice led to 
the suppression of PDGFRβ and KGF expression, an effect not seen in the lung 
homogenates of the sestrin 2 KO mice, which resulted in increased elastin 
production. The resulting reduced lung pathology corroborates the results of a 
previous study using a genetic model of emphysema of impaired TGF-β signaling 
and elastic fiber structure (Wempe et al., 2010), which identified sestrin 2 as a 
repressor of both TGF-β and mTOR. The amplification of PDGFRβ signaling after the 
inactivation of sestrin 2 in the lungs of KO smoke-exposed mice also indicated the 
key role of this pathway in the protection against emphysema. The effect of the 
inactivation of an antioxidant which would theoretically lead to ROS accumulation, 
known to participate in the pathogenesis of COPD, appears contradictory at a first 
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glance. The crucial role of the participation of ROS in signal transduction has been 
demonstrated in the context of a plethora of pathways (Alexander et al., 2010; Bae et 
al., 1999; Choi et al., 2005; Finkel, 2011; Frijhoff et al., 2014; Martindale and 
Holbrook, 2002; Sundaresan et al., 1995). Along these lines, the present study also 
reported that PDGFRβ signaling requires O2
–. The employment of PMA which 
activates O2
– generation by NADPH oxidase supports this conclusion. The different, 
spatial, cellular and subcellular effects of ROS and their time-dependent generation 
can explain the “first glance” contradiction. For example, sestrin 2 could potentially be 
involved in an intrisinc regulation of ROS production and accumulation but its 
upregulation by smoke in COPD lungs leads to an elimination of the amounts of ROS 
(O2
–) needed for the activation of signaling pathways that regulate alveolar 
maintenance. In addition, it has to be taken into account that sestrin 2 also activates 
Nrf2 through the degradation of Keap1 without requiring its catalytic function (Bae et 
al., 2013).  
6.6 Conclusion 
The current study revealed sestrin 2 as a potential therapeutic target for the 
treatment of COPD in mice. Sestrin 2 is upregulated in mice after smoke exposure 
and promotes the development of emphysema by repressing alveolar maintenance 
and repair mechanisms. The mutational inactivation of sestrin 2 in mice prevents 
from the development of emphysema/COPD through the initiation of protective 
mechanisms beginning with the upregulation of PDGFRβ and mTOR signaling and 
concluding with the production of elastin through KGF secretion (Fig. 28). 
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Figure 28. Suggested pathways affected by sestrin 2 inactivation, leading to prevention from 
emphysema and PH.  
The inactivation of sestrin 2 induces alveolar maintenance programs that prevent/ protect from the 
development of emphysema in mice. PDGFRβ plays a central regulatory role in this mechanism that 
begins with the activation of PDGFRβ and can act via mTOR and TGF-β in maintaining the lung 
parenchyma.TSC2: tuberous sclerosis complex 2, PDGFRβ: Platelet-derived growth factor receptor 
beta, KGF: keratinocyte growth factor, TGF-β: transforming growth factor beta, mTOR: mammalian 
target of rapamycin, ATII: alveolar epithelial cells type II. 
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8. SUMMARY 
Chronic obstructive pulmonary disease (COPD) is the fourth ranking cause of 
death worldwide. Despite the extensive efforts that have been made so far, the 
disease remains still incurable due to a lack of therapeutic targets that can prevent 
from the development or even reverse already established disease. Only symptoms 
can be alleviated to some degree, by the current treatments available.  Thus, it still 
causes high morbidity, mortality, disability, health resources depletion and 
socioeconomic burden. One of the major components of COPD is pulmonary 
emphysema caused by the destruction and of alveoli after exposure to noxious 
particles and gases, with cigarette smoke and smoke from heating and cooking being 
the most prominent. The disruption of signaling pathways responsible for lung 
integrity maintenance is thought to be a key point in the development of emphysema. 
Reactive oxygen species generated after the exposure to smoke could disrupt these 
alveolar maintenance programs. It has already been reported that the inactivation of 
the sestrin 2 gene, encoding the member of a family of highly conserved antioxidant 
proteins, can partially rescue the disease phenotype in a genetic mouse model of 
emphysema. This primarily contradictory finding that deletion of an antioxidant 
protein can protect from a genetically induced emphysema was attributed to the 
restoration of impaired TGF-β signaling. Sestrin 2 has also been shown to inhibit 
mTOR. This led to the hypothesis that sestrin 2 might play a role in emphysema 
development in a chronic model of tobacco smoke exposure. To this end, wild type 
and knockout mice were exposed to smoke of a 140mg/m3 total particulate matter 
(TPM) concentration, for 6 hours/day, 5 days/week for a period of 8 months. The wild 
type mice developed pulmonary emphysema as indicated functionally by a significant 
increase in pulmonary compliance and pulmonary hypertension indicated by a 
significant increase in right ventricular systolic pressure. Morphometric evaluation 
also revealed significant structural changes:  increase in airspace% and mean linear 
intercept, and decrease in alveolar septal wall thickness. In contrast the loss of 
function of sestrin 2 resulted in the prevention of emphysema development in the 
knockout mice which demonstrated no significant changes in these parameters when 
compared to respective controls. Sestrin 2 and PDGFRβ mRNA were up- and down- 
regulated respectively in the lungs of wild type mice after smoke exposure. 
Furthermore, sestrin 2 knockout mice exhibited increased numbers of alveolar 
epithelial type II cells and decreased numbers of apoptotic cells after smoke 
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exposure when compared to wild type mice. This study demonstrated that the 
mutational inactivation of sestrin 2 induces PDGFRβ signaling which preserves lung 
integrity by initiating a cascade of events also involving KGF and mTOR signaling 
that results in increased ATII cell proliferation and elastin production. If these data 
are transferrable to the human situation, a sestrin 2 antagonist could be beneficial in 
the treatment of COPD. 
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9. ZUSAMMENFASSUNG 
Derzeit gehört die chronisch obstruktive Lungenerkrankung (COPD) zu der 
vierthäufigsten Todesursache weltweit. Trotz bisherigen umfangreichen 
Bemühungen, gibt es bis heute noch keinen Therapieansatz, der die Entwicklung der 
COPD-Erkrankung verhindert oder gar eine bereits etablierte Erkrankung heilen 
kann. Bisher können lediglich ein Teil der Symptome behandelt werden. Folglich 
verursacht COPD eine hohe Morbidität, Mortalität und Invalidität resultierend in einer 
Erschöpfung von Gesundheitsressourcen und einer sozioökonomische Belastung. Zu 
den Hauptmerkmalen der COPD gehört das Lungenemphysem, charakterisiert durch 
eine Zerstörung der Alveolen aufgrund einer Exposition gegenüber schädlicher 
Partikel und Gase. Zu den bedeutendsten Faktoren scheinen eine Inhalation von 
Zigarettenrauch und eine Verbrennung von Biomasse zum Kochen und Heizen zu 
sein. Derzeit wird eine Dysregulation von Signalwegen zur Erhaltung der 
Lungenintaktheit mit der Entwicklung eines Lungenemphysems in Verbindung 
gebracht. Reaktive Sauerstoffspezies, die nach einer Rauch-Exposition generiert 
werden, könnten diese alveolaren Instandhaltungsmechanismen zerstören. Bisherige 
Studien berichteten, dass eine Inaktivierung des Sestrin-2 Gens, welches ein Mitglied 
der Familie von hoch konservierten antioxidativen Proteinen kodiert, zu einem 
partiellen Schutz des Krankheitsphänotypes in einem genetisches Emphysem-Maus-
Modell führte. Diese zunächst widersprüchliche Erkenntnis, dass eine Inaktivierung 
eines antioxidativen Proteins vor einem genetisch induzierten Emphysems schützt, 
wurde auf die Restoration des beeinträchtigten TGF-β Signalweges zurückgeführt. 
Zusätzlich wurde gezeigt, dass Sestrin-2 mTOR inhibiert. Im Rahmen dieser 
Dissertation sollte daher die Hypothese untersucht werden, ob Sestrin-2 eine Rolle 
bei der Entwicklung eines Lungenemphysems in einem Zigarettenrauch- induzierten 
Emphysemmodell der Maus spielen könnte. Hierfür wurden Wildtyp- und Knockout-
Mäuse 6 Stunden pro Tag, 5 Tage die Woche für 8 Monate bei einer 
Rauchpartikelkonzentration von 140 mg/m³ beraucht. Rauch-exponierte Wildtyp-
Mäuse entwickelten ein Lungenemphysem und eine pulmonale Hypertonie 
funktionell gekennzeichnet durch eine signifikant erhöhte Lungencompliance und 
durch einen signifikanten Anstieg des systolischen rechtsventrikulären Druckes. 
Morphometrische Analysen zeigten zusätzlich signifikante strukturelle 
Veränderungen: eine Erhöhung des Gesamtluftraums der Alveolen und des mittleren 
Abstandes zwischen den Alveolarsepten, sowie eine niedrigere alveolare 
ZUSAMMENFASSUNG     
 90 
Septendicke. Eine Inaktivierung von Sestrin-2 in Knockout-Mäusen verhinderte die 
Entwicklung eines Lungenemphysems, da im Vergleich zu den respektiven 
Kontrolltieren keine signifikanten Veränderungen in den genannten Parametern zu 
sehen waren. Sestrin-2 und PDGFRβ mRNA waren im Lungenhomogenat von 
Wildtyp-Mäusen nach Rauch-Exposition entsprechend hoch- und herunterreguliert. 
Des Weiteren zeigten Rauch-exponierte Sestrin-2 Knockout-Mäuse eine erhöhte 
Anzahl an Alveolarepithelzellen Typ II und eine verminderte Anzahl an apoptotischen 
Zellen im Vergleich zu Wildtyp-Mäusen. Mit dieser Studie konnte gezeigt werden, 
dass ein Knockout von Sestrin-2 den PDGFRβ- Signalweg induziert und somit die 
Lungenintaktheit während einer Rauch-Exposition erhalten bleibt. Hierbei wurden 
Ereigniskaskaden initiiert, die in einer erhöhten ATII Zellproliferation und 
Elastinproduktion resultierten. Diese Ergebnisse werden unter anderem mit dem 
KGF und dem mTOR-Signalweg in Verbindung gebracht. Vorausgesetzt, dass man 
diese Ergebnisse auf den Menschen übertragen kann, könnte ein Sestrin-2 
Antagonist eine neue Behandlungsstrategie für COPD-Patienten sein. 
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